

1 **Mammalian UPF3A and UPF3B activate NMD independently of their EJC binding**

2

3 Zhongxia Yi<sup>1,2</sup>, René M Arvola<sup>1,2</sup>, Sean Myers<sup>3</sup>, Corinne N Dilsavor<sup>2</sup>, Rabab Abu Alhasan<sup>1,2</sup>,  
4 Bayley N Carter<sup>2</sup>, Robert D Patton<sup>1,3</sup>, Ralf Bundschuh<sup>1,3,4,5</sup> and Guramrit Singh<sup>1,2,6</sup>.

5 1. Center for RNA Biology

6 2. Department of Molecular Genetics

7 3. Department of Physics

8 4. Department of Chemistry and Biochemistry

9 5. Division of Hematology, Department of Internal Medicine

10 6. Correspondence: [singh.734@osu.edu](mailto:singh.734@osu.edu)

11 The Ohio State University, Columbus, OH 43210, USA

12

13 **ABSTRACT**

14 Nonsense-mediated mRNA decay (NMD) is governed by the three conserved factors -  
15 UPF1, UPF2 and UPF3. While all three are required for NMD in yeast, UPF3B is  
16 dispensable for NMD in mammals, with its paralog UPF3A suggested to only weakly activate  
17 or even repress NMD due to its weaker binding to the exon junction complex (EJC). Here we  
18 characterize the UPF3B-dependent and -independent NMD in human cell lines knocked-out  
19 of one or both *UPF3* paralogs. We show that in human colorectal cancer HCT116 cells, EJC-  
20 mediated NMD can operate in UPF3B-dependent and -independent manner. While UPF3A  
21 is almost completely dispensable for NMD in wild-type cells, it strongly activates EJC-  
22 mediated NMD in cells lacking UPF3B. Surprisingly, this major NMD branch can operate in  
23 UPF3-independent manner questioning the idea that UPF3 is needed to bridge UPF proteins  
24 to the EJC during NMD. Complementation studies in UPF3 knockout cells further show that  
25 EJC-binding domain of UPF3 paralogs is not essential for NMD. Instead, the conserved mid  
26 domain of UPF3B, previously shown to engage with ribosome release factors, is required for  
27 its full NMD activity. Altogether, UPF3 plays a more active role in NMD than simply being a  
28 bridge between the EJC and the UPF complex.

29

30 **KEYWORDS:** Nonsense-mediated mRNA decay, UPF3, Exon Junction Complex, Nonsense  
31 mutations, Translation termination, mRNA degradation

## 32 INTRODUCTION

33 Nonsense mutations present a challenging obstacle for organisms as they result in  
34 premature termination of protein translation to produce truncated proteins that can be toxic  
35 for the cell. All eukaryotes deploy a conserved mechanism called nonsense-mediated mRNA  
36 decay (NMD) to rapidly degrade mRNAs containing premature termination codons (PTCs) to  
37 limit the production of potential toxic polypeptides. NMD has gained additional importance in  
38 more complex organisms as normal mutation-free mRNAs take advantage of the NMD  
39 machinery to regulate their expression (reviewed in (He & Jacobson, 2015; Karousis &  
40 Mühlemann, 2019; Kishor et al., 2019; Kurosaki et al., 2019)). For example, in mammalian  
41 cells, ~10% of transcriptomes can be regulated by NMD (Mendell et al., 2004; Wittmann et  
42 al., 2006). The key task for the NMD machinery is to differentiate premature translation  
43 termination from normal translation termination on both pathogenic as well as natural  
44 mRNAs that are degraded by this pathway. How the NMD machinery makes such a  
45 discrimination remains to be completely understood.

46 NMD depends on a set of core factors - UPF1, UPF2 and UPF3 that are conserved  
47 throughout eukaryotes. When translation terminates prematurely and much upstream of  
48 normal 3'-untranslated region (3'UTR) and polyA-tail, UPF factors can recognize such  
49 termination events as premature via mechanisms that have been conceptualized into two  
50 possible (non-mutually exclusive) models. One model suggests that termination in an altered  
51 3'UTR context can compromise normal termination promoting interaction between release  
52 factors eRF3/eRF1 and the polyA-tail binding protein (PABP) (Amrani et al., 2004; Behm-  
53 Ansmant et al., 2007; Eberle et al., 2008; Ivanov et al., 2008; Peixeiro et al., 2012; Singh et  
54 al., 2008). Instead, UPF1 can engage with eRFs and initiate NMD (Kashima et al., 2006).  
55 According to the other model, longer 3'UTRs of NMD-targeted mRNAs may serve as a  
56 distinction between normal and premature termination. By recruiting more UPF1, the central  
57 NMD activator that can non-specifically bind RNA in a length-dependent manner, longer  
58 3'UTRs increase the likelihood of UPF1 engagement with terminating ribosome (Hogg &  
59 Goff, 2010). While the majority of available evidence points to a more direct role for UPF1 in  
60 engaging with release factors and terminating ribosome (Ivanov et al., 2008; Kashima et al.,  
61 2006; Singh et al., 2008), a recent study shows that UPF3B (a UPF3 paralog) has a direct  
62 involvement in termination reaction in human cell extracts (Neu-Yilik et al., 2017).  
63 Nevertheless, the precise order of events and the mechanistic details of UPF functions at  
64 individual steps during premature termination remain poorly understood.

65 In mammalian cells, the NMD pathway has become more complex as it is tightly  
66 linked to pre-mRNA splicing via the exon junction complex (EJC), which has gained  
67 significant importance for NMD activation. The EJC is deposited on the mRNA exon-exon  
68 junctions during splicing and is exported along with the mRNAs to the cytoplasm where they  
69 are stripped-off mRNAs by translating ribosomes (reviewed in (Boehm & Gehring, 2016; Hir  
70 et al., 2016; Woodward et al., 2017)). However, when PTCs lead to early translation  
71 termination, one or more EJCs that remain bound downstream of a terminated ribosome can  
72 stimulate NMD. As UPF3 has evolved to directly interact with the EJC, the presence of EJC-  
73 UPF3-UPF2 complex in 3'UTRs can promote UPF1 activation and premature termination via  
74 either of the two NMD models. Notably, in these models UPF3 is mainly viewed as a bridge  
75 between the UPF and EJC proteins (Chamieh et al., 2008). However, the functional  
76 relevance of such a bridging function, or if UPF3-EJC interaction serves another role,  
77 remains to be seen.

78 While all three UPF proteins are essential for NMD in yeast (Celik et al., 2017; He et  
79 al., 1997), UPF3 appears to have become less important for NMD in more complex  
80 organisms and some NMD can proceed even in its absence (reviewed in (Yi et al., 2021)).  
81 Unlike UPF1 or UPF2, a complete loss of UPF3 in *Drosophila* does not affect viability and  
82 has only a modest effect on NMD (Avery et al., 2011). In mammals, there exist two UPF3  
83 paralogs, UPF3A and UPF3B, and available evidence suggest that UPF3B provides the  
84 main UPF3 activity due to its better EJC binding ability (Kunz et al., 2006). UPF3A can  
85 function as a weak NMD activator and can help compensate for UPF3B function (Chan et  
86 al., 2009). However, a recent study has suggested that UPF3A may primarily function as an

87 NMD repressor, potentially by sequestering UPF2 away from NMD complexes via its strong  
88 UPF2 binding but weaker EJC binding (Shum et al., 2016). Surprisingly, despite being the  
89 dominant NMD activating UPF3 paralog, UPF3B knockout mice are largely normal albeit  
90 with some neurological defects (Huang et al., 2011, 2018). Similarly, UPF3B inactivating  
91 mutations in humans are non-lethal although they cause intellectual disability (Laumonnier et  
92 al., 2010; Tarpey et al., 2007) and are associated with neurodevelopmental disorders such  
93 as autism spectrum disorders and schizophrenia (Addington et al., 2011; Lynch et al., 2012;  
94 Xu et al., 2013). These observations suggest that while UPF3B is important for key biological  
95 processes, its effects on NMD are likely to be peripheral since a total loss of NMD is lethal in  
96 vertebrates (Medghalchi et al., 2001; Weischenfeldt et al., 2008). Previous studies in human  
97 cell lines and mice models have shown that UPF3B is not required for NMD of several  
98 mRNAs, indicating that there exists a UPF3B-independent NMD pathway (Chan et al., 2007;  
99 Gehring et al., 2005; Huang et al., 2011). How NMD can function in the absence of UPF3  
100 and how prevalent is such UPF3-independent NMD remains largely unknown.

101 UPF3B function in NMD might be further affected by specific EJC compositions. Our  
102 previous work has demonstrated that EJC composition is heterogenous and, during different  
103 phases of mRNA lifecycle, EJC associates with a distinct set of peripheral factors (Mabin et  
104 al., 2018). EJC co-factor RNPS1 does not co-exist in the same complex with another key  
105 EJC factor CASC3. Mass spectrometry of RNPS1 and CASC3 containing EJCs showed that  
106 CASC3 but not RNPS1 preferentially associates with UPF3B (Mabin et al., 2018). Consistent  
107 with this observation, a recent report found a much-reduced EJC-UPF3B association in  
108 CASC3 knockout HEK293 cells (Gerbracht et al., 2020). Together, these observations  
109 suggest a link between EJC composition and UPF3B-mediated NMD. The contribution of  
110 such a link to NMD and its underlying molecular basis remains to be fully understood.

111 Here, we created UPF3B knockout human cell lines with CRISPR-Cas9 to study  
112 NMD in the presence and absence of UPF3B and to understand the relative flux through the  
113 UPF3B-dependent and UPF3B-independent branches of NMD. We find that most transcripts  
114 with 3'UTR EJCs can undergo NMD in both UPF3B dependent and independent manner. In  
115 the absence of UPF3B, and only under such conditions, UPF3A becomes responsible for a  
116 significant portion of UPF3B-independent NMD. We find that while CASC3-containing EJC  
117 can moderately affect UPF3-mediated NMD, it does not appear to be the major determinant  
118 for efficient UPF3-dependent NMD. Surprisingly, our comparative analysis of UPF3A and  
119 UPF3B functions in NMD suggest that UPF3 proteins remain potent NMD activators even  
120 without their ability to bind EJC, hinting that another UPF3 function, such as its modulation of  
121 translation termination reaction, may be its primary and a more conserved mode of activating  
122 NMD.

## 123 RESULTS

### 124 UPF3B is required but not necessary for EJC-mediated NMD

125 To study UPF3B-independent NMD, we used CRISPR-Cas9 based gene editing to generate  
126 two independent *UPF3B* knockout ( $3B^{KO}$ ) alleles in human colorectal carcinoma HCT116  
127 cells, a near diploid cell line with only one copy of *UPF3B*. In the first approach, we deleted  
128 ~8 kilobase genomic region of *UPF3B* locus that spans exons 1-4 and encodes the UPF2-  
129 binding domain of UPF3B ( $3B^{KO\#1}$ ; Figure 1A). We reason that the loss of this key functional  
130 domain will lead to a complete loss of UPF3B function during NMD. As expected, in  $3B^{KO\#1}$   
131 cells, a smaller protein deleted of amino acids 20-155 is expressed and that too only at  
132 ~12% of the full-length protein in wild-type cells (Figure 1B). For the  $3B^{KO\#2}$  allele, we used  
133 homology-directed repair to insert immediately downstream of the *UPF3B* start codon a  
134 puromycin resistance marker followed by a polyadenylation signal that would terminate  
135 transcription and prevent expression of the downstream sequence (Figure 1A). The resulting  
136 puromycin resistant  $3B^{KO\#2}$  cells completely lack UPF3B (Figure 1B). A qPCR survey in the  
137 two knockout cell lines revealed that mRNA levels of several previously characterized NMD-  
138 regulated genes are similarly upregulated whereas a subset of these genes remain largely  
139 unchanged in the two cell lines (Figure S1A). Thus, the HCT116 UPF3B knockout cells  
140 represent an appropriate model to study UPF3B-dependent and -independent NMD.

141 To identify transcriptome-wide targets of UPF3B-dependent and -independent NMD  
142 branches, we performed RNA-Seq from wild-type (WT) and  $3B^{KO\#1}$  HCT116 cells transfected  
143 with either control siRNA (siNC) or UPF1 targeting siRNA (siUPF1) (Figure S1B). The  
144 mRNAs upregulated in UPF3B knockout cells as compared to WT cells can be considered  
145 UPF3B-dependent NMD targets. Since UPF1 should be required for all NMD, mRNAs  
146 upregulated after UPF1 knockdown (KD) in UPF3B knockout cells can be considered as  
147 UPF3B-independent NMD targets. We quantified gene expression at mRNA isoform level in  
148 these RNA-seq samples and carried out differential expression analyses. As expected after  
149 loss of an mRNA repressive factor such as UPF3B, the number of upregulated transcripts in  
150  $3B^{KO\#1}$  cells as compared to WT cells is much higher as compared to those downregulated  
151 (Figure S1C). However, the effects on the transcriptome after UPF3B loss are smaller as  
152 compared to the UPF1 knockdown (Figures S1D, E), suggesting a more restricted role of  
153 UPF3B than UPF1 in gene regulation.

154 Short- or long-term depletion of gene regulatory proteins such as UPF factors can  
155 cause indirect changes in gene expression (Tani et al., 2012). Indeed, we observe a similar  
156 number of up- and down- regulated transcripts after 48-hour UPF1 knockdown in HCT116  
157 cells (Figure S1E). To minimize the impact of such indirect effects on transcriptome-wide  
158 quantification of NMD factor contributions to the pathway, we focused on a specific class of  
159 genes that produce two types of transcript isoforms, one with an exon-exon junction  $\geq 50$   
160 nucleotides downstream of a stop codon (PTC+ transcripts) and one that lacks this well-  
161 known NMD-inducing feature (PTC- transcripts). Any change in NMD is expected to alter  
162 only the PTC+ isoforms whereas any indirect effects on gene expression are expected to  
163 similarly impact both the PTC+ and PTC- isoforms. A comparison of transcript isoform levels  
164 in  $3B^{KO\#1}$  versus control cells show a significant upregulation of PTC+ isoforms over PTC-  
165 isoforms (Figure 1C), similar to the trend observed in UPF1-KD versus control cells (Figure  
166 1D). We confirmed the specific and significant (in most cases) upregulation of PTC+  
167 isoforms as compared to the PTC- isoforms of several genes in UPF3B-KO cells via a qPCR  
168 assay (Figure 1E and Figure S1F). These results suggest that UPF3B is required for the  
169 efficient downregulation of EJC-dependent NMD targets in HCT116 cells.

170 We next examined the extent to which the EJC-mediated NMD pathway remains  
171 functional in our UPF3B knockout cells. If EJC-mediated NMD can still occur in the absence  
172 of UPF3B, we expect further upregulation of PTC+ isoforms as compared to PTC- isoforms  
173 when the NMD pathway is further compromised by UPF1 depletion in UPF3B knockout cells.  
174 In line with this prediction, we observe a significant global upregulation of PTC+ transcripts  
175 as compared to their PTC- counterparts after UPF1 knockdown in  $3B^{KO\#1}$  cells (Figure 1F),  
176 suggesting that EJC-mediated NMD can still occur in the absence of UPF3B.

177 In addition to EJC downstream of a stop codon, NMD can also be induced by long  
178 3'UTRs (Eberle et al., 2008; Hogg & Goff, 2010; Singh et al., 2008). To test if UPF3B is also  
179 required for NMD of mRNAs with extended 3'UTRs, we divided transcripts based on their  
180 3'UTR length into three groups each with a similar number of transcripts. As expected, UPF1  
181 knockdown causes a significant upregulation of the group of transcripts with the longest  
182 3'UTRs as compared to those with medium or short 3'UTRs (Figure S1G). Surprisingly,  
183 UPF3B knockout shows a negligible effect on the relative abundance of long 3'UTR-  
184 containing transcripts (Figure S1H). Therefore, while UPF3B is important but not essential  
185 for the EJC-induced NMD in HCT116 cells, it likely plays an insignificant role in long 3'UTR-  
186 mediated NMD in these cells.

187

### 188 **UPF3A replaces UPF3B in EJC-UPF complexes in UPF3B knockout cells**

189 We next sought to address how can EJC-dependent NMD operate in human cells in the  
190 absence of UPF3B, which is widely believed to act as a bridge between the UPF proteins  
191 and the downstream EJC. To investigate the NMD complexes that assemble in the presence  
192 or absence of UPF3B, we used CRISPR-Cas9 gene editing to insert a FLAG affinity tag-  
193 encoding sequence immediately downstream of the start codon at the endogenous *UPF1*  
194 locus in both WT and UPF3B knockout cells. This facilitates FLAG immunoprecipitation (IP)  
195 of the UPF1-containing complexes from the two cell lines. We find that while in wild-type  
196 cells, UPF1 mainly associates with UPF3B and only minimally with its paralog UPF3A, in  
197 UPF3B knockout cells, UPF1-UPF3A association is dramatically enhanced (Figure 2A).  
198 Importantly, the enhanced UPF1-UPF3A association is independent of RNA. As expected  
199 based on the previous observations (Chan et al., 2009; Tarpey et al., 2007), UPF3A is  
200 upregulated 3.5-fold in UPF3B knockout cells (Figure 2B). Notably, in RNA-Seq data from  
201 3B<sup>KO#1</sup> cells, *UPF3A* mRNA shows 1.8-fold increase. Thus, overall increase in UPF3A in  
202 UPF3B knockout cells likely occurs both at the mRNA and protein level. Similar to its  
203 enhanced association with the UPF complex in the absence of UPF3B, UPF3A also shows  
204 increased co-IP with core EJC factor EIF4A3 (Figure 2C) and peripheral protein CASC3  
205 (Figure S2A) in UPF3B knockout cells.

206 To validate that UPF3A is indeed incorporated into EJC-UPF complex, we inserted a  
207 FLAG affinity tag into the *MAGOH* locus and a MYC affinity tag into the *UPF2* locus. We  
208 then knocked out either UPF3A or UPF3B in this dual-tagged cell line by inserting an  
209 antibiotic resistance gene followed by polyadenylation signal. From these cells, a tandem IP  
210 of FLAG-MAGOH followed by MYC-UPF2 can isolate the EJC-UPF complex from WT,  
211 UPF3A knockout or UPF3B knockout cells. In the WT and UPF3A knockout cells, UPF3B is  
212 the major paralog incorporated into the EJC-UPF complex as indicated by co-IP of UPF3B  
213 and CASC3 (Figure S2B). In comparison, in the UPF3B knockout cells, UPF3A is  
214 incorporated into the complex at a much higher level (Figure S2B). We also notice that there  
215 is an overall decrease in the abundance of the UPF2-EJC complex in UPF3B knockout cells  
216 as compared to WT or UPF3A knockout cells (Figure S2B). Together, these data suggest  
217 that UPF3A is capable of simultaneously engaging with the UPF and EJC proteins  
218 particularly in the absence of UPF3B.

219

### 220 **UPF3A compensates for UPF3B function in NMD**

221 Previous evidence from human cells suggests that UPF3A can act as a weak NMD activator  
222 particularly in cells with reduced UPF3B levels (Chan et al., 2009; Kunz et al., 2006).  
223 Interestingly, when overexpressed in wild-type cells, UPF3A can inhibit NMD (Chan et al.,  
224 2009; Shum et al., 2016). Our results above suggest that UPF3A may provide UPF3 function  
225 during NMD in the absence of UPF3B. To evaluate contribution of UPF3A to NMD in wild-  
226 type and UPF3B knockout cells, we knocked-down UPF3A in WT and 3B<sup>KO#1</sup> cells (Figure  
227 S2C) and performed RNA-Seq to quantify global transcript levels as above. We observe that  
228 while UPF3A knockdown in WT HCT116 cells leads to widespread changes in the  
229 transcriptome (Figure S2D), changes between PTC+ and PTC- isoforms are negligible  
230 (Figure 2D). These data suggest that in wild-type HCT116 cells, UPF3A is largely  
231 inconsequential for NMD and neither acts as an NMD enhancer or repressor. In contrast to

232 the wild-type cells, when abundance of PTC+ and PTC- transcripts is compared in UPF3B  
233 knockout cells after UPF3A or control knockdown, we observe a specific and significant  
234 upregulation of the PTC+ transcript group in cells depleted of both UPF3A and UPF3B as  
235 compared to cells lacking only UPF3B (Figure 2E). These data suggest that UPF3A  
236 possesses the ability to activate NMD that becomes prominent only in the absence of  
237 UPF3B while in wild-type cells UPF3A potentially has a function outside NMD.

238 We next tested if UPF3A and UPF3B affect similar or distinct set of NMD targets. We  
239 defined UPF3B-dependent targets as PTC+ transcripts that show significant and  $\geq 1.5$ -fold  
240 upregulation in  $3B^{KO\#1}$  cells as compared to WT cells, and compared their change upon  
241 additional UPF3A knockdown versus control knockdown in  $3B^{KO\#1}$  cells. As control, we  
242 compared change in the corresponding PTC- group under the same conditions. We find that  
243 UPF3B-dependent PTC+ group shows a strong upregulation after UPF3A knockdown in  
244  $3B^{KO\#1}$  cells (Figure 2F). At the same time, the UPF3B-independent transcripts, which  
245 change  $\leq 1.2$ -fold in  $3B^{KO\#1}$  cells as compared to WT cells, are also similarly affected by  
246 UPF3A knockdown in  $3B^{KO\#1}$  cells, albeit to a lesser extent (Figure 2G). Thus, in the  
247 absence of UPF3B, UPF3A acts on a similar set of mRNAs as UPF3B, and NMD targets that  
248 are insensitive to UPF3B are only weakly affected by UPF3A.

249 To further validate the UPF3A function in NMD, we created UPF3A knockout cells  
250 ( $3A^{KO}$ ) either by deleting the genomic region encompassing exons 1 and 2 and part of intron  
251 2 or by inserting a blasticidin resistance marker followed by a polyadenylation signal (Figure  
252 S2E,F). We also created a UPF3A+3B double knockout ( $3^{DKO}$ ) cells by combining the two  
253 antibiotic resistance markers for each gene (Figure S2F). qPCR based quantification of  
254 PTC+ transcripts that are upregulated upon UPF3B loss (Figure 1E and Figure S1F) and  
255 their corresponding PTC- isoforms shows that the loss of UPF3A has minimal or no effect on  
256 the abundance of any of the PTC+ isoforms (Figure 2G and S2F) confirming that UPF3A is  
257 dispensable for NMD of this subset of transcripts. In comparison, all the PTC+ transcripts  
258 show the highest upregulation in the UPF3 double knockout cell lines (Figure 2G and Figure  
259 S2F) reflecting the additive effects of loss of UPF3A and UPF3B on NMD of these transcripts  
260 (except for *NFKB1B*, which shows a minor additive effect). Together, these results show that  
261 UPF3A works in the EJC-dependent NMD but only in the absence of UPF3B. Hereafter, we  
262 will use UPF3 to refer to both the paralogs.

263 We next tested if the minimal effect of the loss of UPF3B on long 3'UTR-containing  
264 mRNAs (Figure S1G,H) was due to the compensation of UPF3 function by UPF3A in UPF3B  
265 knockout cells. We observe that UPF3A knockdown in UPF3B knockout cells or in WT cells  
266 does not lead to an upregulation of long 3'UTR transcripts (Figure S2H). In turn, UPF3A  
267 might even mildly inhibit long 3'UTR-mediated NMD as UPF3A knockdown leads to a  
268 modest but significant downregulation of the transcript group with the longest 3'UTRs in both  
269 WT and UPF3B knockout HCT116 cells (Figure S2I). Due to the minimal impact of UPF3  
270 proteins on long 3'UTR-mediated NMD in HCT116 cells, from hereon we focus only on  
271 UPF3 function in EJC-mediated NMD.

272

### 273 **CASC3-containing EJC potentiates UPF3-dependent NMD**

274 We next tested the contribution of other factors from the EJC-mediated NMD pathway to  
275 UPF3 function in this branch of NMD. We first focused on CASC3-containing EJC as  
276 previous observations from human embryonic kidney (HEK293) cells suggest that there  
277 exists a functional synergy between the CASC3-containing EJC and UPF3B (Gerbracht et  
278 al., 2020; Mabin et al., 2018). To test if CASC3-UPF3B preferential association is also  
279 present in other cell types, we overexpressed in HeLa cells either wild-type CASC3 or a  
280 mutant CASC3 (HDAA) that is unable to associate with the EJC core (Ballut et al., 2005).  
281 We observe an enhanced EJC-UPF3B association in HeLa cells when wild-type CASC3 but  
282 not the CASC3 HDAA mutant is overexpressed (Figure 3A, compare lanes 9-10 with lanes  
283 11-12). To test if CASC3 overexpression can similarly enhance EJC-UPF3A association, we  
284 created a UPF3B knockout in HeLa cells by deleting a ~1.4 kb region of the *UPF3B* locus  
285 encompassing part of its promoter region, first exon and part of the first intron (Figure S3A  
286 and S3B). UPF3B knockout in HeLa cells results in a similar enhancement of EJC-UPF3A

287 association (Figure S3C) as observed in HCT116 cells (Figure 2C). Furthermore,  
288 overexpressing wild-type CASC3 but not the CASC3 HDAA mutant in UPF3B knockout  
289 HeLa cells enhances UPF3A co-IP with EIF4A3 (Figure 3B, compare lanes 9-10 with lanes  
290 11-12). Additionally, CASC3 knockdown reduces both EJC-UPF3B and EJC-UPF3A  
291 association in wild-type and UPF3B knockout HeLa cells (Figure S3D). Together, these  
292 results suggest that CASC3 promotes the EJC-UPF3 association.

293 To investigate CASC3-UPF3B association in HCT116 cells, we inserted FLAG  
294 sequence into endogenous *UPF3B*, *CASC3* and *MAGOH* loci to express FLAG-tagged  
295 translational fusions of these factors. From these cells, we performed FLAG IPs followed by  
296 a second IP of the EJC core factor EIF4A3 to isolate compositionally different EJCs. We find  
297 that CASC3 is strongly enriched in UPF3B-containing EJC as compared to EJCs purified via  
298 its core factors, which likely are a mixture of EJCs of distinct compositions (Figure 3C,  
299 compare lanes 4 and 5). We hypothesized that preferential association between CASC3 and  
300 UPF3B will enrich the EJCs containing the two proteins on a similar set of transcripts. To test  
301 this possibility, we carried out RIPiT-Seq (RNA IP in tandem followed by high-throughput  
302 sequencing (Singh et al., 2012)) to identify the RNA footprints of FLAG-MAGOH:EIF4A3,  
303 FLAG-UPF3B:EIF4A3 and FLAG-CASC3:EIF4A3 complexes. As expected, the RNA  
304 footprints of the three complexes show a strong enrichment at the exon 3' ends at the  
305 expected EJC binding site (Figure 3D and Figure S3E). To test if UPF3B and CASC3 exhibit  
306 synergistic binding to transcripts, we first individually compared CASC3:EIF4A3 and  
307 UPF3B:EIF4A3 occupancy to the EJC core (MAGOH:EIF4A3) occupancy. Genes that are  
308 enriched in either UPF3B-EJC or CASC3-EJC as compared to the EJC core show a large  
309 and significant overlap (Figure 3E). In contrast, little overlap is detected between genes that  
310 are UPF3B-depleted and CASC3-enriched, or vice versa (Figure S3F,G). Strikingly, we  
311 observe a strong positive correlation between transcriptome wide UPF3B and CASC3  
312 binding relative to the EJC core (Figure 3F) suggesting that UPF3B and CASC3  
313 preferentially bind to a similar set of transcripts.

314 We next asked if UPF3B-EJC occupancy influences NMD efficiency, i.e., does  
315 increased UPF3B-EJC binding to an mRNA lead to more efficient NMD? For this analysis,  
316 we selected genes that express at least one PTC+ isoform, and for NMD efficiency of each  
317 gene, we used the highest fold change observed for its PTC+ isoform in UPF3 depleted cells  
318 (UPF3A knockdown in 3B<sup>KO#1</sup> cells) as compared to control (WT cells with negative control  
319 knockdown). Upon comparison of NMD efficiency estimates for these genes to their EJC  
320 core-normalized UPF3B-EJC occupancy, we do not observe any appreciable correlation  
321 between the two metrics (Figure 3G). Similar relationship is seen between NMD efficiency  
322 and mRNA expression-normalized UPF3B (Figure S3H) or EJC core (Figure S3I)  
323 occupancy. Together, these data suggest that in wild-type HCT116 cells UPF3B or EJC  
324 occupancy are unlikely to be limiting factors for NMD.

325 To directly investigate the dependence of UPF3-dependent NMD on CASC3, we  
326 measured the levels of UPF3B-dependent PTC+ transcripts in a HCT116 cell line where  
327 CASC3 expression is completely knocked out by frameshifting indels around its start codon  
328 (Figure S3J). We observe a moderate increase in abundance of *ILK*, *RPS9* and *SRSF3*  
329 PTC+ transcripts while no such change is observed in the case of *NFKB1B* PTC+ isoform, an  
330 NMD target that is the least affected by the loss of UPF3 (Figure 2G). Thus, normal CASC3  
331 levels are important for efficient UPF3-dependent NMD.

### 332 **UPF2 and UPF3 function in EJC-mediated NMD is interdependent**

333 To test if the UPF3 paralogs are required by UPF2 for its function in EJC-mediated NMD, we  
334 knocked down UPF2 in wild-type and in UPF3A and UPF3B double knockout HCT116 cells  
335 (Figure S4A). While UPF2 knockdown in wild-type cells alters expression of more than two  
336 thousand transcripts (Figure S4B), only less than a quarter are changed after UPF2  
337 knockdown in UPF3 double knockout cells (Figure S4C), suggesting that UPF2 depletion in  
338 cells lacking UPF3 causes fewer additional changes in gene expression. Such an effect is  
339 more obvious for EJC-mediated NMD substrates. While a significant upregulation of PTC+  
340 isoforms is seen upon UPF2 knockdown in wild-type cells (Figure 4A), no such change is  
341

342 observed between PTC+ and PTC- isoforms upon depleting UPF2 in UPF3 double knockout  
343 cells (Figure 4B). These data suggest that UPF2 function in EJC-mediated NMD depends on  
344 UPF3, and that these factors act on a shared set of transcripts in the EJC-mediated NMD  
345 branch.

346

### 347 **EJC-mediated NMD can completely bypass the need for UPF3**

348 It has been previously reported that NMD of a TCR- $\beta$  reporter mRNA and a handful of  
349 endogenous NMD substrates can occur independently of UPF3 in human cells (Chan et al.,  
350 2007). However, in these experiments UPF3 paralogs were depleted using RNA interference  
351 thus leaving open a possibility that some residual UPF3 proteins may still be able to sustain  
352 NMD. We therefore tested the existence and extent of any EJC-mediated NMD that can still  
353 occur in UPF3 double knockout cells. We observe that, like in wild-type cells (Figure 4C),  
354 UPF1 knockdown in UPF3 double knockdown cells leads to further upregulation of PTC+  
355 isoforms compared to PTC- isoforms (Figure 4D), suggesting that some EJC-mediated NMD  
356 can still function in the complete absence of both UPF3 proteins. Our data provides a strong  
357 support for the existence of a UPF3-independent NMD branch, which also is unlikely to  
358 require UPF2.

359 It remains unknown if UPF3-dependent and -independent NMD branches target  
360 different mRNAs or if the two branches target same set of mRNAs that show variable NMD  
361 commitment in the presence/absence/variable levels of UPF3 proteins. To test this idea, we  
362 separated PTC+ mRNAs into two groups (i) a UPF3-dependent group that is significantly  
363 upregulated  $\geq 1.5$ -fold in  $3^{DKO}$  cells, and (ii) a UPF3-independent group that changes  $\leq 1.2$ -  
364 fold in  $3^{DKO}$  cells. If UPF3-independent NMD branch targets distinct mRNAs that are still  
365 degraded by NMD in  $3^{DKO}$  cells, then these PTC+ mRNAs are expected to be upregulated  
366 upon UPF1 knockdown in  $3^{DKO}$  cells. However, we observe that the UPF3-independent  
367 PTC+ mRNAs show only a very minor upregulation as compared to their PTC- counterparts  
368 when  $3^{DKO}$  cells are depleted of UPF1 (Figure 4E). In contrast, the UPF3-dependent group of  
369 PTC+ mRNAs shows a more prominent upregulation under these conditions (Figure 4F).  
370 These data indicate that PTC+ mRNAs that undergo UPF3-dependent NMD can still be  
371 targeted by the NMD pathway in UPF3-independent manner, perhaps at a reduced rate.

372

### 373 **UPF3A and UPF3B differ in their NMD activity that is dictated by their mid domains**

374 Although previous work suggests that in human cells UPF3A can suppress NMD of certain  
375 endogenous genes (Shum et al., 2016), we did not observe such an activity of UPF3A in our  
376 analysis of EJC-mediated NMD targets in HCT116 cells (Figures 2 and S2). Notably, among  
377 previous reports of UPF3A's NMD suppressing activity in human cells, most robust NMD  
378 inhibition was observed in the case of a  $\beta$ -globin NMD reporter mRNA under UPF3A  
379 overexpression conditions (Chan et al., 2009; Shum et al., 2016). Indeed, we confirmed that  
380  $\beta$ -globin mRNA reporter with a PTC at codon 39 ( $\beta 39$ ) is stabilized when UPF3A is  
381 overexpressed in wild-type HeLa cells. In comparison, UPF3B overexpression shows little  
382 effect on the reporter mRNA half-life as compared to the control (Figure 5A). Additionally,  
383 these results also highlight that despite UPF3A's ability to compensate for UPF3B function in  
384 NMD, the two paralogs have notable differences in their NMD activity. To further investigate  
385 these differences, we compared the ability of UPF3A and UPF3B to rescue the strong defect  
386 in  $\beta 39$  reporter mRNA NMD in UPF3B knockout HeLa cells as compared to the wild-type  
387 cells (Figure 5B). While overexpressing exogenous UPF3B in UPF3B knockout cells fully  
388 rescues  $\beta 39$  reporter mRNA decay, overexpressing UPF3A in these cells only mildly  
389 rescues the decay of the reporter (Figure 5B). Together, these data suggest that, while  
390 UPF3A can functionally compensate for UPF3B, the two paralogs exhibit different NMD  
391 activities.

392 We next sought to identify the molecular basis of the differences in the NMD activity  
393 of the two human UPF3 paralogs. We created a series of domain swap mutants where each  
394 UPF3A domain is replaced by the corresponding sequence from UPF3B (Figure 5C) with the  
395 goal to identify the UPF3B domain that will confer UPF3A with a full UPF3B-like NMD  
396 activity. An expectation based on the previous work is that the lower UPF3A NMD activity



397 results from its weaker EJC binding compared to UPF3B due to an arginine-to-alanine  
398 change at position 423 in the EJC binding motif (EBM) within the carboxy (C)-terminal  
399 domain (Kunz et al., 2006). However, we find that in the UPF3B knockout cells  
400 overexpressing a UPF3A mutant with the UPF3B C-terminal domain, the steady-state  $\beta$ 39  
401 mRNA levels are similar to those in the cells transfected with wild-type UPF3A and ~3-fold  
402 higher than the cells expressing UPF3B (Figure 5D). Surprisingly, the UPF3A mutant that  
403 carries the UPF3B mid-domain (region between the UPF2 binding domain and the C-  
404 terminal domain) lowers the  $\beta$ 39 mRNA steady-state levels to a similar extent as UPF3B  
405 (Figure 5D). Thus, we conclude that the UPF3B mid-domain, and not its EBM-containing C-  
406 terminal domain, might underlie the difference between UPF3A and UPF3B NMD activity.

407 To compare the EJC and UPF binding ability of the UPF3A swap mutants to the wild-  
408 type UPF3 paralogs, we created stable cell lines in the UPF3 double knockout background  
409 using the PiggyBac transposon system to express FLAG-tagged UPF3 proteins and the  
410 UPF3A swap mutants. EIF4A3 IP from these cells shows that, as previously reported,  
411 UPF3A shows weaker binding to the EJC as compared to UPF3B (Figure 5E, compare lanes  
412 7 and 8). Interestingly, both UPF3A-3BMid and UPF3A-3BC mutants show an increased  
413 association with the EJC (Figure 5E and Figure S5A) even though only UPF3A-3BMid  
414 mutant can rescue the decay of NMD reporter mRNA (Figure 5D). We conclude that while  
415 the UPF3B mid and C-terminal domains can independently enhance EJC association,  
416 possibly via distinct mechanisms, the difference in NMD activity of UPF3A and UPF3B  
417 primarily stems from their mid-domains. A previous report has suggested that UPF3B mid-  
418 domain (smaller than as defined here) can associate directly with eRF3 (GSPT1) protein in  
419 vitro (Neu-Yilik et al., 2017). However, FLAG-IP of UPF3A or UPF3B fails to co-IP detectable  
420 eRF3 (Figure S5B), possibly due to the transient nature of such association in HCT116 cells.  
421

#### 422 **EJC binding is largely dispensable for UPF3 NMD activity**

423 While we do observe stabilization of NMD mRNA after UPF3A overexpression, our data  
424 cannot conclude if such “NMD repressor” activity is physiologically present. Interestingly,  
425 sequence alignment of human, mouse and rat UPF3 C-terminal domains reveals that while  
426 the domain is conserved among the three species, mouse and rat UPF3A lack most or all  
427 residues required for EJC-binding whereas human UPF3A retains most of the EJC-binding  
428 residues (Figure 6A). Consistently, IP of FLAG-tagged mouse UPF3A (mUPF3A) from 3<sup>DKO</sup>  
429 cells shows a near complete absence of EJC factors in the immunoprecipitates, while human  
430 UPF3A (hUPF3A) can still associate with EJC proteins albeit more weakly as compared to  
431 human UPF3B (Figure 6B). Importantly, all three proteins show a comparable association  
432 with UPF2. Furthermore, mUPF3A transiently expressed in HeLa cells also fails to co-IP any  
433 detectable levels of EJC proteins (Figure S6). We conclude that over the course of evolution,  
434 the UPF3A proteins in mouse, and most likely in rat as well, have lost their EJC binding  
435 ability.

436 We hypothesized that due to its loss of EJC binding activity, mouse UPF3A may not  
437 be able to compensate for *UPF3B* loss in human cells, which might reconcile the difference  
438 between our observation and the previous study (Shum et al., 2016). Surprisingly, however,  
439 when we expressed mouse or human UPF3A proteins, or human UPF3B as a control, in  
440 3<sup>DKO</sup> cell lines, all three UPF3 proteins fully rescue the NMD of all but one PTC<sup>+</sup> isoforms we  
441 examined (Figure 6C). Mouse UPF3A expression in 3<sup>DKO</sup> cells leads to partial rescue only in  
442 the case of the *ILK* PTC<sup>+</sup> isoform, which shows the strongest UPF3B dependence (Figures  
443 1E, 2G and 6C) and full rescue by either human UPF3A or UPF3B (Figure 6C). These data  
444 provide the first evidence that EJC-binding is not required for the NMD activity of UPF3 in  
445 human cells and may play a more secondary role in EJC-mediated NMD.

## 446 **DISCUSSION**

447 Of the three core NMD factors, UPF3 has evolved most rapidly in eukaryotes. In multicellular  
448 organisms, on the one hand it appears to have lost its essentiality for NMD activity, and on  
449 the other, it has gained an ability to interact with the NMD-stimulating EJC. Furthermore, in  
450 vertebrates, *UPF3* gene has duplicated into paralogous *UPF3A* and *UPF3B*, which have  
451 diverged in their EJC binding ability. The emergence of these variations in *UPF3* raises  
452 several questions: What is UPF3's primary function in NMD? If NMD can occur without EJC  
453 in yeast, what is the role of EJC interaction in UPF3 function? How do the two paralogs  
454 contribute to UPF3 activity in the pathway? How can NMD function in the absence of  
455 UPF3B, or UPF3 altogether, and how prevalent is such an NMD activity? Our work here  
456 using complete UPF3A and UPF3B loss-of-function human cell lines adds to the  
457 experimental evidence that is leading toward answers to these important questions. Based  
458 on the existing data and our results reported here, we present an updated model of UPF3A  
459 and UPF3B function in mammalian NMD (Figure 7), which is further elaborated below.

460

### 461 **UPF3A is an NMD activator**

462 The early studies on UPF3A suggested that it acts as a weak NMD activator in human cells  
463 (Chan et al., 2009; Kunz et al., 2006). However, the recent work by Shum et al using mouse  
464 models and cell lines has instead suggested that the UPF3 gene duplication fueled neo-  
465 functionalization of UPF3A into an NMD repressor (Shum et al., 2016). In the model  
466 proposed by Shum et al, weak EJC binding by UPF3A sequesters UPF2 away from the  
467 NMD complex thereby leading to NMD inhibition (Shum et al., 2016). In our work here in  
468 human (HCT116) cells, we do not observe any negative (or positive) effects on the levels of  
469 PTC-containing mRNAs when UPF3A is depleted via RNA interference (Figure 2D) or when  
470 it is completely knocked out (Figure 2G) in wild-type cells. These data suggest that UPF3A  
471 does not interfere with UPF3B function in EJC-mediated NMD, and hence does not act as  
472 NMD repressor in these cells. On the contrary, several lines of evidence from our work  
473 suggests that UPF3A acts as an NMD activator, particularly in the absence of UPF3B. In  
474 cells lacking UPF3B, UPF3A is upregulated (Figure 2B) (Chan et al., 2009; Nguyen et al.,  
475 2012; Tarpey et al., 2007), and its incorporation in EJC-UPF complexes is dramatically  
476 enhanced (Figures 2A,2C, S2A-B) (Chan et al., 2009). Further, a partial or complete UPF3A  
477 depletion in UPF3B lacking cells leads to robust upregulation of EJC-mediated NMD targets,  
478 both at a global level (Figure 2E) and at an individual transcript level (Figures 2G, S2F). This  
479 evidence suggests that in the absence of UPF3B, UPF3A engages with the NMD machinery  
480 to sustain the EJC-mediated NMD pathway. Moreover, we find that UPF3A is comparable to  
481 UPF3B in its ability to rescue EJC-mediated NMD of various endogenous PTC-containing  
482 mRNAs (Figure 6C) although some notable differences between the two paralogs are  
483 observed (see below). Additionally, UPF3A's impact on NMD overlaps with that of UPF3B  
484 (Figure 2F) (Figure 2G). Importantly, a parallel study by Wallmeroth et al. also shows that  
485 UPF3A functions as a NMD activator in HEK293 cells that lack UPF3B. The redundancy  
486 between UPF3A and UPF3B is more exacerbated in these cells as only depletion of both the  
487 proteins leads to transcriptome-wide NMD inhibition (Wallmeroth et al., 2021). This evidence  
488 also suggests that in human patients with UPF3B inactivating mutations, UPF3A can likely  
489 fill in for UPF3B in most of the EJC-dependent NMD, which is critical for several  
490 physiological processes (e.g., hematopoiesis (Weischenfeldt et al., 2008)). However, UPF3A  
491 cannot compensate for UPF3B functions in select contexts such as brain development  
492 possibly due to differences in function or gene expression patterns of the paralogs.

493 While our findings point to an NMD activating role for UPF3A, in certain specific  
494 contexts, UPF3A can inhibit NMD. For example, under artificial conditions, UPF3A  
495 overexpression in wild-type HeLa cells slows down NMD of the  $\beta$ -globin reporter mRNA  
496 (Figure 5A) (Chan et al., 2009). Such conditions do arise in specific cell types (e.g. mouse

497 germ cells) and/or developmental stages (e.g. early mouse embryogenesis,  
498 spermatogenesis) where UPF3A expression is dramatically increased. An important context  
499 is male germ cells where UPF3A is likely the main source of UPF3 activity due to the  
500 presumed silencing of *UPF3B* due to meiotic X-chromosome inactivation (Turner, 2007).  
501 Shum et al showed that high UPF3A to UPF3B ratio in these cells inhibits NMD of selected  
502 NMD targets. (Shum et al., 2016). It will be important to assess UPF3A function in NMD in  
503 germ cells at a fuller global scale to determine if NMD repression is its dominant function in  
504 these cells or if it acts both as NMD activator and repressor, perhaps in transcript specific  
505 manner. Notably, Shum et al. did find that UPF3A can activate NMD of a small subset of  
506 transcripts in a mouse stem cell line. Our findings here also shed light on the mechanistic  
507 basis of potential NMD inhibitory action of UPF3A. We show that mouse UPF3A, which  
508 completely lacks EJC binding activity (Figure 6B), can still rescue NMD of most endogenous  
509 mRNA targets in UPF3 double knockout cells to the same level as the human UPF3A or  
510 UPF3B proteins. This ability of mouse UPF3A to activate NMD without EJC binding suggests  
511 that it is unlikely that weak or no EJC binding by UPF3A proteins can cause NMD  
512 repression. Instead, UPF3A may inhibit NMD potentially by outcompeting the stronger NMD  
513 factor UPF3B (Figure 5A).

514 The basis of conservation of two similar UPF3 paralogs remains to be fully  
515 appreciated. It is possible that in addition to UPF3A's NMD repressive activity, its ability to  
516 activate NMD, or even its NMD-independent functions (Figure S2D; (Ma et al., 2019)) may  
517 have contributed to its conservation through vertebrate evolution.

518

#### 519 **Dispensability of UPF3-EJC interaction warrants a revised model for UPF3 function in** 520 **NMD**

521 Current NMD models suggest that in the EJC-mediated NMD, UPF3B acts as a bridging  
522 molecule between the UPF proteins and the downstream EJC. This view is based on  
523 UPF3B's ability to directly bind to UPF2 via its N-terminal RRM domain (Kadlec et al., 2004)  
524 and to a composite surface on the EJC core via the EJC binding motif in its C-terminus  
525 (Chamieh et al., 2008). Surprisingly, we find that mouse UPF3A, which is missing most of  
526 the EJC binding motif (Figure 6A) and hence lacks any detectable EJC binding (Figure 6B),  
527 is still capable of rescuing NMD of several PTC-containing mRNAs (Figure 6C). Additionally,  
528 replacing the weaker EJC binding C-terminal region of human UPF3A with the stronger EJC  
529 binding C-terminal domain of human UPF3B does not improve the NMD function of the  
530 chimeric UPF3A protein (Figures 5C-E). Thus, our findings suggest that UPF3 proteins  
531 (UPF3A or UPF3B) can activate NMD without EJC binding, thereby challenging the  
532 decades-old bridging model for UPF3 function in the pathway.

533 We propose that EJC binding by UPF3 proteins is not a primary activity of these  
534 proteins in the NMD pathway. It is more likely that EJC binding is important to recruit UPF3  
535 (and perhaps UPF2) to mRNA exon-exon junctions (Figure 3, Figure 7) to increase the  
536 likelihood of NMD activation by yet another UPF3 function when translation terminates at  
537 PTC (Figure 7). The recruitment of both human UPF3 paralogs to mRNA via the EJC can be  
538 enhanced by CASC3 (Figures 3, S3 and 7), which is a defining component of a  
539 compositionally distinct EJC (Mabin et al., 2018). How CASC3 enhances EJC interaction  
540 with UPF3 remains to be seen. The current understanding of CASC3 and UPF3B interaction  
541 with the EJC core is limited to the small regions of the two proteins that directly contact the  
542 EJC (Buchwald et al., 2010; Melero et al., 2012). It is possible that additional interactions  
543 between other regions of CASC3 (e.g. N- or C-terminal domains on either side of the EJC  
544 binding SELOR domain) and UPF3 (e.g. mid-domain, which enhances EJC interaction  
545 (Figure 5D)) contribute to EJC association of UPF3. Although the effect of CASC3 loss on  
546 UPF3-mediated NMD targets appear to be modest (Figure 3H), modulation of CASC3 levels,  
547 for example by miR128 in neuronal cells (Bruno et al., 2011), can regulate UPF3-dependent

548 NMD. How can the need for UPF3 recruitment to mRNAs via EJC be bypassed? It is  
549 possible that at higher UPF3 expression levels, such as those achieved in the rescue  
550 experiments in Figure 6, this prior mRNA recruitment of UPF3 becomes dispensable, and  
551 the primary function of UPF3 is sufficient to drive NMD. Interestingly, compromised EJC  
552 recruitment of UPF3B in cells depleted of ICE1, which also aids in UPF3B-EJC interaction,  
553 can be similarly overcome by UPF3B overexpression (Baird et al., 2018).

554 What is the primary role of UPF3 proteins in NMD activation? Early studies from  
555 yeast revealed that these proteins, including UPF3, can physically engage with termination  
556 factor eRF3 (Wang et al., 2001). These data suggested a role for UPF proteins in  
557 discrimination between normal and premature termination events, but the detail of such  
558 mechanisms has remained elusive. A recent investigation using an in vitro assay to monitor  
559 translation termination found that UPF3B, but not UPF1 or UPF2, can slow down the  
560 termination reaction and promote disassembly of the terminated ribosome (Neu-Yilik et al.,  
561 2017). Interestingly, this report shows that UPF3B can directly interact with eRF3 and eRF1.  
562 In fact, the direct in vitro UPF3B-eRF3 interaction is mediated by a UPF3B region that falls  
563 within the segment that we define here as the mid-domain (Figure 5C). How these  
564 translation termination-linked UPF3 activities and interactions contribute to NMD was  
565 however unknown. Our work here shows the importance of the mid-domain for efficient NMD  
566 (Figure 5D), even though we do not detect an association between UPF3B and eRF3 in  
567 HCT116 cells (Figure S5B). It is possible that this interaction is transient in nature and is  
568 reliably detectable only when the two proteins are exogenously expressed at much higher  
569 levels as in the previous work (Neu-Yilik et al., 2017). It also remains to be seen if  
570 differences in NMD activity of UPF3A and UPF3B is governed by the differences in their mid-  
571 domains to engage with termination factors. Nonetheless, our data and the findings of  
572 Wallmeroth et al. in the accompanying paper along with the published work (Neu-Yilik et al.,  
573 2017) indicate that the UPF3 mid-domain plays an important role in NMD activation  
574 (Wallmeroth et al., 2021). The functional relevance of this poorly characterized region of the  
575 UPF3 proteins is further underscored by several missense *UPF3B* mutations that fall within  
576 this domain in individuals with neurodevelopmental disorders (Alrahbeni et al., 2015).

577 Once translation terminates in a context where signals promoting normal termination  
578 are diminished (e.g. weakened PABPC1-eRF interaction, (Ivanov et al., 2008; Peixeiro et al.,  
579 2012; Singh et al., 2008)) or where signals promoting premature termination are increased  
580 (e.g. more frequent 3'UTR binding of UPF1 and/or increased local concentration of  
581 UPF3/UPF2 by the downstream EJC), early steps in the NMD pathway ensue. Perhaps,  
582 these include recruitment of UPF3B to the termination complex via its interactions with eRFs,  
583 which leads to slowing down of the termination reaction. It is notable that premature  
584 termination has been proposed to be more inefficient than normal termination (He &  
585 Jacobson, 2015) even though the direct observation and mechanistic basis of such  
586 phenomenon remains elusive (Karousis et al., 2020). UPF1 and UPF2 have also been  
587 shown to interact with termination factors and may play a role in this process (Ivanov et al.,  
588 2008; Kashima et al., 2006; López-Perrote et al., 2016; Singh et al., 2012; Wang et al.,  
589 2001). Once termination reaction is deemed to be premature, yet another function of UPF3B  
590 can be to promote ribosome dissociation and/or recycling (Neu-Yilik et al., 2017). While it  
591 remains to be seen when in relation to termination reaction do critical NMD events such as  
592 UPF1 phosphorylation and UPF1 ATPase activation occur, it is likely that UPF3B continues  
593 to function at these downstream steps in the NMD pathway. It will be an important goal for  
594 future studies to precisely define the order and mechanism of steps that lead to NMD  
595 activation, and the contribution of UPF3 proteins to these steps. It will be also important to  
596 determine UPF3-independent mechanisms whereby the 3'UTR bound EJCs enhance  
597 premature termination and NMD (Figure 7).

598

599 **UPF3-dependent and -independent NMD branches**

600 Even though UPF3 (UPF3B) plays a critical role in activating efficient NMD, multiple lines of  
601 evidence suggests that NMD in many organisms can proceed independently of UPF3. For  
602 example, unlike UPF1 and UPF2, UPF3 is not essential for viability in flies and its loss has  
603 only modest effect on many NMD targets (Avery et al., 2011). Similarly, some mRNAs can  
604 undergo NMD in human cells with dramatically reduced UPF3B levels or no UPF3B at all  
605 (Chan et al., 2007; Nguyen et al., 2012; Tarpey et al., 2007). Moreover, few mRNAs were  
606 only mildly affected upon severe depletion of both UPF3A and UPF3B from human cells  
607 (Chan et al., 2007, 2009). Our work now provides most definitive evidence for existence for  
608 UPF3-independent NMD as the PTC-containing mRNAs can be further upregulated upon  
609 UPF1 knockdown in cells completely lacking both UPF3A and UPF3B (Figure 4D). This  
610 UPF3-independent NMD is likely to be also UPF2-independent as the same set of  
611 transcripts are not affected by UPF2 depletion in UPF3 double knockout cells (Figure 4B).  
612 How could NMD proceed in the absence of UPF3 (and UPF2) remains to be investigated.

613 Intriguingly, we observe that the same set of NMD-targeted transcripts that are UPF3  
614 sensitive can be further upregulated upon UPF1 depletion in UPF3 lacking cells (Figure 4F).  
615 Thus, these mRNAs can still undergo EJC-mediated NMD in the absence of UPF3.  
616 However, the NMD targets that are unaffected in UPF3 knockout cells remain largely  
617 unperturbed as a group under UPF1 limiting conditions (Figure 4E). This suggests that  
618 rather than targeting different sets of mRNAs, UPF3-dependent and UPF3-independent  
619 NMD branches are more likely to reflect fractions of same mRNAs that commit to NMD in  
620 UPF3-dependent or -independent manner. Further, in the parallel study, Wallmeroth et al.  
621 show that even UPF3B activities like UPF2 or EJC binding can function in a redundant  
622 manner to induce NMD (Wallmeroth et al., 2021). The mechanistic basis and functional  
623 significance of such a stochastic/conditional function of NMD factors in the pathway  
624 represents yet another exciting frontier for future work.

## 625 **MATERIALS AND METHODS**

### 626 **Plasmids**

627 For CRISPR-Cas9-mediated antibiotic resistance marker and polyadenylation signal knock-  
628 in experiments (for gene knockouts), PX330 plasmid was used for introducing Cas9-  
629 mediated cuts. PX330 was a gift from Feng Zhang (Addgene plasmid # 42230;  
630 <http://n2t.net/addgene:42230>; RRID:Addgene\_42230). Guide RNA sequence was cloned as  
631 previously described (Ran et al., 2013). For donor plasmids, 300-500 bp left and right  
632 homology region from gene-of-interest, and puromycin resistance marker-Bovine Growth  
633 Hormone polyA-signal (amplified from pMK232 (Natsume et al., 2016)) or blasticidin  
634 resistance marker-Simian Virus 40 polyA-signal (amplified from pcDNA6/TR (Thermo  
635 Fisher)) were cloned into pTwist-Amp (Twist Bioscience) using Golden Gate Assembly  
636 (NEB). pMK232 was a gift from Masato Kanemaki (Addgene plasmid # 72834;  
637 <http://n2t.net/addgene:72834>; RRID:Addgene\_72834)

638 For the UPF3 WT and chimeric protein plasmids, human UPF3A (CCDS9543.1)  
639 domains, N-terminus (2-62), UPF2-binding domain (63-160), Mid (163-385), and C-terminus  
640 (386-476), are replaced by corresponding human UPF3B (CCDS14587.1) domains, N-  
641 terminus (2-45), UPF2-binding domain (46-143), Mid (146-370), and C-terminus (371-470).  
642 UPF3 and chimeric proteins DNA are cloned into pcDNA3ez-FLAG plasmid using BamHI  
643 and XbaI as previously described (Mabin et al., 2018; Singh et al., 2007). For CASC3  
644 expression plasmid, full length CASC3 and CASC3-HDAA mutant are cloned into pcDNA3ez  
645 with EcoRI and XbaI.

646 For PiggyBac transposase expression plasmid, hyPBase sequence (Yusa et al.,  
647 2011) was codon optimized for human cell expression and a synthetic DNA was cloned into  
648 mammalian expression vector pTwist-CMV-Beta-Globin by Twist Bioscience. PiggyBac  
649 transposon plasmids with Tet-ON system are made from PB-TRE-EGFP-EF1a-rtTA plasmid  
650 in Addgene #104454, which was a gift from Volker Buskamp (Addgene plasmid # 104454;  
651 <http://n2t.net/addgene:104454>; RRID:Addgene\_104454). EGFP inserts in this plasmid were  
652 replaced by restriction sites NheI and NotI, and the puromycin resistance marker was  
653 replaced by neomycin resistance marker using Gibson Assembly (NEB). FLAG-tagged gene  
654 of interests are moved to the PiggyBac plasmid from pcDNA3 using NheI and NotI site.

655 Plasmids expressing tet-inducible and control  $\beta$ -globin NMD reporters were  
656 previously described (Lykke-Andersen et al., 2000; Singh et al., 2007).

657

### 658 **Cell Culture**

659 HCT116 (ATCC) and HeLa Tet-Off (Takara) cell lines were cultured at 37°C and 5% carbon  
660 dioxide in a humidified chamber. McCoy's 5A (Modified) Medium (Gibco) for HCT116 cells  
661 and Dulbecco's Modified Eagle Medium with High Glucose (Gibco) for HeLa Tet-Off cells  
662 were supplemented with 10% Fetal Bovine Serum (Sigma) and 1% Penicillin-Streptomycin  
663 (Fisher).

664

### 665 **Cell transfection for transient or stable expression**

666 For protein knockdown using siRNA, 1.6  $\mu$ l of RNAiMAX, 60 pmol of siRNA and 200  $\mu$ l  
667 OMEM was incubated for 20 mins following manufacturer protocol.  $3 \times 10^5$  cells were then  
668 added to the transfection mixture in a 6-well plate. 48 hours after initial transfection, total  
669 RNA was harvested.

670 For transient expression of proteins in HeLa cells, plasmids were transfected using  
671 JetPrime (PolyPlus) transfection reagent following manufacturer protocol with one fifth of  
672 recommended DNA (e.g. 200 ng DNA was used per well of a 12-well plate if the user  
673 manual recommend 1000ng DNA). 24-48 hours later, cells were harvested for  
674 immunoprecipitation or northern blot.

675 To make stable PiggyBac cell lines, 286 ng of pTwist-CMV-BetaGlobin-hyPBase  
676 plasmid was co-transfected with 714 ng of transposon plasmid (neomycin resistant) that  
677 carries the gene of interest into a 6 well plate with  $3 \times 10^5$  cells seeded a day before. 48  
678 hours post transfection, cells were trypsinized and expanded under 600  $\mu\text{g}/\text{ml}$  G418  
679 selection for 2 weeks. Polyclonal cells resistant to G418 were then expanded and frozen for  
680 further experiments. To induce the protein expression from polyclonal PiggyBac stable cells,  
681 100 ng/ml of final doxycycline was added to the medium and cells were harvested after 24  
682 hours for immunoprecipitation or RNA extraction.

683

### 684 **Electroporation**

685 For electroporating CRISPR-Cas9 complexes into HeLa or HCT116 cells,  $\sim 2.5 \times 10^5$  cells  
686 were washed in PBS and resuspended in Ingenio Electroporation Solution (Mirus) with 1-2  
687  $\mu\text{M}$  RNP complex to a final volume of 50  $\mu\text{l}$ . The electroporation mix was then transferred to  
688 a Gene Pulser Electroporation Cuvette (0.2-cm gap). Electroporation was performed with  
689 Gene Pulser Xcell Electroporation Systems (Bio-Rad) under the following conditions: HCT  
690 116 cells: 120 V, 13 msec/per pulse, 2 pulses with 1 sec interval; HeLa cells: 130V, 950  $\mu\text{F}$   
691 capacitance, exponential decay pulse.

692

### 693 **CRISPR-Cas9 mediated knockout and knockin**

694 For UPF3B<sup>KO#1</sup>, two pX330 plasmids carrying two guide RNA sequences were co-  
695 transfected into HCT116 cells using JetOptimus (PolyPlus) as described above. After 2-3  
696 weeks, single clones were isolated and screened for genomic deletion.

697 For UPF3A<sup>KO#1</sup>, UPF3B<sup>KO#3</sup> and UPF3B<sup>KO#4</sup>, two guide RNAs per gene were  
698 synthesized (IDT or Synthego). 50 pmol of Cas9 recombinant protein (Berkeley Q3) and 60  
699 pmol of each guide RNA were incubated for  $\sim 20$  mins in 10  $\mu\text{l}$  reaction supplemented with  
700 Ingenio Electroporation Solution.  $2.5 \times 10^5$  cells were then mixed with CRISPR-Cas9 RNP  
701 complex and a final volume of 50  $\mu\text{l}$  was used for the final electroporation reaction as  
702 described above. After 2-3 weeks, single clones were isolated and screened for genomic  
703 deletion.

704 For resistance marker-based knockouts, donor plasmids carrying antibiotic  
705 resistance genes and homology arms along with pX330 plasmid expressing guide RNAs that  
706 targeted Cas9 close to the insert site were co-transfected using JetOptimus (PolyPlus).

707 For knock-in of small affinity tags, HCT116 cells were synchronized using 2  $\mu\text{g}/\text{mL}$   
708 aphidicolin overnight and the synchronization was released 4 hours before the  
709 electroporation of CRISPR RNP complex. CRISPR RNP complex was prepared as  
710 described above and supplemented with 150 pmol of ssODN (50nt homology arms each  
711 side of the affinity tag). Electroporation was performed using Gene Pulser Xcell  
712 Electroporation System as described above.

713 For MYC-UPF2, we were unable to achieve efficient knock-in without selection. We  
714 used a resistance marker-based knock-in approach where a donor plasmid carrying  
715 hygromycin resistance marker-P2A-MYC tag in frame with UPF2 ORF was co-transfected  
716 with pX330 expressing guide RNA targeting a site close to the UPF2 start codon.  
717 Hygromycin resistant clones were isolated and screened for correct insert. All DNA  
718 sequences edited via CRISPR-Cas9 were confirmed by Sanger sequencing.

719

### 720 **RNA extraction**

721 Cells were homogenized in TRI-reagent and RNA was extracted using one of three different  
722 methods. (1) RNA extraction was done following the manufacturer's protocol, and then the  
723 extracted RNA was treated with 2 units of DNase I (NEB) and further cleaned up via phenol-  
724 chloroform (pH 4.3) extraction and standard ethanol precipitation. (2) One volume of ethanol  
725 was added to the TRI-reagent homogenized sample and the mixture was loaded onto a

726 silica column (Epoch). The flowthrough was discarded and the column was washed once  
727 with high salt wash buffer (1.2 M Guanidine Thiocyanate; 10 mM Tris-HCl pH 7.0; 66%  
728 Ethanol) and twice with low salt wash buffer (10 mM Tris-HCl pH 7.0; 80% Ethanol). RNAs  
729 were eluted with water and subject to DNase I treatment as above. To the DNase I digested  
730 RNA, three volumes of RNA binding buffer (5.5 M Guanidine Thiocyanate; 0.55 M Sodium  
731 Acetate; 10 mM EDTA) and 4 volumes of ethanol were added. The mixture was then loaded  
732 into a silica column as above and washed twice with low salt wash buffer. RNA was then  
733 eluted in water. (3) All steps followed the second method with two exceptions: the silica  
734 columns were replaced with magnetic carboxylate modified beads (Cytiva) and the DNase I  
735 digestion was performed in the presence of beads (RNA gets eluted from beads upon  
736 addition of DNase I digestion mix). RNA was then re-bound to the magnetic beads by adding  
737 5 volumes of ethanol. RNAs are then washed with low salt wash buffer twice before eluting  
738 in water.

739

#### 740 **RT-qPCR**

741 1.5 µg total RNA was reverse transcribed using Maxima RNaseH Minus Reverse  
742 Transcriptase following manufacturer's protocol except that only 0.4 µl of the reverse  
743 transcriptase was added instead of 1 µl. cDNAs were then diluted to 5 ng/µl, and 3 µl of  
744 diluted cDNA was used per reaction. qPCR reactions were set up using iTaq Universal  
745 SYBR Green Supermix (Bio-Rad) with triplicates of 10 µl per reaction. qPCR was performed  
746 on a CFX-connect (Bio-Rad) equipment.

747

#### 748 **β-globin reporter assays and Northern blots**

749 For pulse-chase assays, 75,000 HeLa Tet-off cells were plated in each well of a 12-well  
750 plate. After 24h, reporter mRNA and protein expression plasmids were transfected using  
751 JetPrime, following manufacturer's protocol (using 3:1 ratio of reagent to µg DNA). Cells  
752 were transfected with 200 ng pTet2 β39 plasmid, 20 ng β-GAP internal control, 10 ng  
753 pcDNA3ez-YFP, and 20 ng pcDNA3ez-FLAG-UPF3A/B. 100 ng/ml Tetracycline was used to  
754 suppress β39 expression. After 24h, tetracycline was removed to induce β39 expression  
755 overnight (~16h). Tetracycline (1 µg/ml) was added, and cells were harvested in 0.5 ml  
756 TRIzol at indicated time points. For steady state assays, cells were transfected and induced  
757 in the same way as the reporter decay assay. At the day of harvesting, 1 µg/ml of  
758 tetracycline was added to all cells and cells are harvested 4-6 hours post transcription shut-  
759 off. RNA was extracted as above and Northern blotting was performed as described  
760 previously (Mabin et al., 2018).

761

#### 762 **Protein Immunoprecipitation**

763 Cells were washed with PBS and lysed with Gentle Hypotonic Lysis Buffer (20 mM Tris-HCl  
764 pH 7.5; 15 mM NaCl; 10 mM EDTA; 0.1% Triton X-100; 1× protease inhibitor cocktail; EDTA  
765 was replaced with 0.6 mM MgCl<sub>2</sub> for magnesium-dependent IP (Fig. S6B)). A short 4-6 secs  
766 sonication pulse (10% amplitude) was applied to solubilize the chromatin fraction. 2-5 µl of  
767 the FLAG magnetic beads (Sigma) for FLAG-IP, and ~1 µg primary antibody conjugated with  
768 protein-A dynabeads (Thermo Fisher) for EIF4A3-IP or CASC3-IP, were added to cell  
769 lysates and nutated at 4°C for 30-60 mins. Magnetic beads were then washed 8 times with  
770 Isotonic Wash Buffer (20 mM Tris-HCl pH 7.5; 150 mM NaCl; 0.1% IGEPAL CA-630). FLAG  
771 proteins were eluted for 10-20 mins with 250 ug/ml 3× FLAG peptide (APEX-BIO) in Isotonic  
772 Wash Buffer at 37°C. Primary antibody conjugated with protein-A beads were eluted for 5  
773 mins in Clear Sample Buffer (100 mM Tris-HCl pH 6.8; 4% SDS; 10 mM EDTA) at 37°C.

774

#### 775 **Total RNA-Seq library construction**



776 800 ng of total RNA was rRNA-depleted using RiboCop rRNA Depletion Kit V1.3 (Lexogen)  
777 following manufacturer's protocol. Libraries were then constructed using CORALL Total  
778 RNA-Seq Library Prep Kit (Lexogen). Libraries were quantified on RNA TapeStation and  
779 mixed at equimolar ratio for paired-end (2 × 150bp) sequencing using HiSeq4000  
780 (Novogene) platform. Due to the relative short length of our libraries, we used only read 1  
781 sequence for downstream analysis. We had three batches of experiments performed at  
782 different times, and only RNA-Seq samples sequenced at the same time were compared  
783 during the downstream analysis.

784

### 785 **Total RNA-Seq analysis**

786 A reference script for mapping RNA-Seq libraries to the reference genome was kindly  
787 provided by Lexogen. For every fastq file, the first 10bp of each read (UMI) were extracted  
788 and appended to the header line using a custom Awk script and saved to a new file together  
789 with the remainder of the reads starting at position 13. Adapter trimming was then performed  
790 with cutadapt (Martin, 2011) for the sequence  
791 "AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC". Trimmed reads were aligned to the  
792 reference genome (GRCh38.p13) using STAR aligner (Dobin et al., 2013). Each output bam  
793 file was then indexed with samtools (Danecek et al., 2021) and deduplicated with UMI-tools  
794 (Smith et al., 2017) using the umi\_tools dedup command with the [--method=unique --  
795 multimapping-detection-method=NH] options. The fastq file with deduplicated reads was  
796 then extracted from the deduplicated bam file using samtools. Next, deduplicated fastq files  
797 served as input into pseudoalignment tool Kallisto (Bray et al., 2016) to quantify transcript  
798 abundance based on the Ensembl release 100 transcript reference. Tximport (Soneson et  
799 al., 2015) was used to extract transcript abundance from Kallisto results and generate count  
800 matrices for DESeq2. TPMs calculated from Kallisto results for each transcript were  
801 averaged for each experimental condition. We filtered out all the transcripts that have TPM  
802 less than 1 in all experimental conditions. After filtering out the transcripts, we use the  
803 RUVSeq (Risso et al., 2014) package [RUVs-method] to remove unwanted variation  
804 following the instruction manual. DESeq2 (Love et al., 2014) was then used to identify  
805 differentially expressed transcripts and calculate their fold changes.

806

### 807 **PTC+ and PTC- transcript lists**

808 To generate a list of PTC+ transcripts and their PTC- counterparts, we used a custom  
809 Python script that takes all human transcripts in Ensembl annotation (version 100) along with  
810 their exon and 3'UTR coordinates to annotate each transcript as PTC+ if the 3'UTR begins  
811 more than 50 nt upstream of the exon junction or if there are more than one exon junctions  
812 downstream of the stop codon.

813

### 814 **RIPiT-Seq**

815 RIPiT-Seq was performed as described (Yi & Singh, 2021). Four biological replicates each  
816 were performed for FLAG-MAGOH:EIF4A3, FLAG-UPF3B:EIF4A3, and FLAG-  
817 CASC3:EIF4A3 and sequenced on the HiSeq4000 (Novogene) platform.

818

### 819 **RIPiT-Seq quantification and differential occupancy analysis**

820 Four replicates each of MAGOH-EJC, CASC3-EJC, and UPF3B-EJC RIPiT-Seq were  
821 obtained, for a total of 12 samples. RIPiT-Seq data analysis was performed similarly to our  
822 previous studies (Mabin et al., 2018; Patton et al., 2020). In short, the first 8 bp of each read  
823 (UMI) were extracted and appended to the header line using a custom Awk script and saved  
824 to a new file together with the remainder of the reads starting at position 9. Cutadapt (Martin,  
825 2011) [--discard-untrimmed -g ^CC --no-indels | --discard-untrimmed -O 12 -a  
826 TGGAATTCTCGGGTGCCAAGG -] is used to retain any reads start with "CC" and ends with

827 mirCat-33 adapter. Fastq files are further cleaned up by only retaining reads unable to align  
828 to a custom reference of abundant RNA sequences using STAR aligner [--  
829 outReadsUnmapped Fastx]. Trimmed reads were aligned to the reference genome  
830 (GRCh38.p13) using STAR aligner (Dobin et al., 2013). EJC signal for each gene was  
831 quantified using reads that overlap with the canonical EJC site (-39 to -9bp of 3' end of non-  
832 last exon) and was averaged over all canonical EJC sites of a transcript (i.e., intron count).  
833 Any gene with EJC counts RPKM  $\leq 5$  was removed. Gene-level EJC signal was then input  
834 into DESeq2 for differential gene expression analysis (Love et al., 2014).

835

### 836 **Meta-exon analysis**

837 RIPiT replicates and the exon annotation were used to compute total read depth as a  
838 function of distance from the 5' start and 3' end of each exon. Genes with less than 10 reads  
839 were discarded. Each remaining gene's coverage distribution was normalized by the total  
840 number of reads of that gene and such normalized distributions were averaged across all  
841 genes. The average read distribution was then plotted with respect to the distance to the  
842 start or the end of the exon.

843

### 844 **Expression Normalized RIPiT Comparisons**

845 Reads mapping to the canonical EJC region for each RIPiT-Seq sample were normalized by  
846 the total length of canonical region for each gene, and this length normalized EJC signal for  
847 each gene was divided by the RPKM of that gene from total RNA-seq. The resulting  
848 expression normalized signal for the CASC3, UPF3B, and MAGOH RIPiT-Seq were then  
849 correlated to the NMD efficiency of each gene that contains at least one PTC+ and one  
850 PTC- isoform. NMD efficiency of each gene is marked by the highest fold change of the  
851 PTC+ isoform in 3B<sup>KO#1</sup>:siUPF3A compared to WT:siNC.

## 852 **ACKNOWLEDGMENTS**

853 We would like to thank Dr. Jens Lykke-Andersen for antibodies and plasmids, and Dr. Harold  
854 Fisk for kindly sharing the electroporation system with us. We would like to thank Dr. Niels  
855 Gehring for communicating unpublished results. Z.Y. is supported by Pelotonia Graduate  
856 Fellowship program and Center for RNA Biology Fellowship program at OSU. R.M.A. is  
857 supported by President's Postdoctoral Scholars program and Pelotonia Postdoctoral  
858 Fellowship program at OSU. S.M. is supported by Department of Physics Undergraduate  
859 Summer Research Scholarship at OSU. C.N.D. is supported by Pelotonia Undergraduate  
860 Fellowship program and College of Arts and Sciences Undergraduate Research Scholarship  
861 at OSU. B.N.C. is supported by Center for RNA Biology Early-Stage Researcher Fellowship  
862 at OSU. This work is supported by NIH grant R01-GM120209 to G.S. We acknowledge an  
863 allocation of computation resources from the Ohio Supercomputer Center. Instrumentation  
864 was supported by NIH grant S10-OD023582.

865

## 866 **AUTHOR CONTRIBUTIONS**

867 Conceptualization, Z.Y. and G.S.; Investigation, Z.Y., R.M.A., S.M., C.N.D., R.A.A., B.N.C.,  
868 and R.D.P.; Writing - Original Draft, Z.Y. and G.S.; Writing - Review and Editing, Z.Y.,  
869 R.M.A., S.M., R.D.P., R.B., and G.S.; Supervision, R.B. and G.S.

870

## 871 **DATA AVAILABILITY**

872 RNA-Seq and RIPit-Seq data are uploaded to GEO: GSE115977, which will be made  
873 accessible upon the acceptance of the manuscript.

874

## 875 **CONFLICTS OF INTEREST**

876 The authors declare no conflict of interest.

877

## 878 **REFERENCES**

- 879 Addington, A. M., Gauthier, J., Piton, A., Hamdan, F. F., Raymond, A., Gogtay, N., Miller, R.,  
880 Tossell, J., Bakalar, J., Germain, G., Gochman, P., Long, R., Rapoport, J. L., &  
881 Rouleau, G. A. (2011). A novel frameshift mutation in UPF3B identified in brothers  
882 affected with childhood onset schizophrenia and autism spectrum disorders.  
883 *Molecular Psychiatry*, 16(3), 238–239. <https://doi.org/10.1038/mp.2010.59>
- 884 Alrahbeni, T., Sartor, F., Anderson, J., Miedzybrodzka, Z., McCaig, C., & Müller, B. (2015).  
885 Full UPF3B function is critical for neuronal differentiation of neural stem cells.  
886 *Molecular Brain*, 8(1), 33. <https://doi.org/10.1186/s13041-015-0122-1>
- 887 Amrani, N., Ganesan, R., Kervestin, S., Mangus, D. A., Ghosh, S., & Jacobson, A. (2004). A  
888 faux 3'-UTR promotes aberrant termination and triggers nonsense-mediated mRNA  
889 decay. *Nature*, 432(7013), 112–118. <https://doi.org/10.1038/nature03060>
- 890 Avery, P., Vicente-Crespo, M., Francis, D., Nashchekina, O., Alonso, C. R., & Palacios, I. M.  
891 (2011). Drosophila Upf1 and Upf2 loss of function inhibits cell growth and causes  
892 animal death in a Upf3-independent manner. *RNA*, 17(4), 624–638.  
893 <https://doi.org/10.1261/rna.2404211>
- 894 Baird, T. D., Cheng, K. C.-C., Chen, Y.-C., Buehler, E., Martin, S. E., Inglese, J., & Hogg, J.  
895 R. (2018). ICE1 promotes the link between splicing and nonsense-mediated mRNA  
896 decay. *ELife*, 7, e33178. <https://doi.org/10.7554/eLife.33178>
- 897 Ballut, L., Marchadier, B., Baguet, A., Tomasetto, C., Séraphin, B., & Le Hir, H. (2005). The  
898 exon junction core complex is locked onto RNA by inhibition of eIF4AIII ATPase  
899 activity. *Nature Structural & Molecular Biology*, 12(10), 861–869.  
900 <https://doi.org/10.1038/nsmb990>
- 901 Behm-Ansmant, I., Gatfield, D., Rehwinkel, J., Hilgers, V., & Izaurralde, E. (2007). A  
902 conserved role for cytoplasmic poly(A)-binding protein 1 (PABPC1) in nonsense-  
903 mediated mRNA decay. *The EMBO Journal*, 26(6), 1591–1601.  
904 <https://doi.org/10.1038/sj.emboj.7601588>

- 905 Boehm, V., & Gehring, N. H. (2016). Exon Junction Complexes: Supervising the Gene  
906 Expression Assembly Line. *Trends in Genetics*, 32(11), 724–735.  
907 <https://doi.org/10.1016/j.tig.2016.09.003>
- 908 Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016). Near-optimal probabilistic RNA-  
909 seq quantification. *Nature Biotechnology*, 34(5), 525–527.  
910 <https://doi.org/10.1038/nbt.3519>
- 911 Bruno, I. G., Karam, R., Huang, L., Bhardwaj, A., Lou, C. H., Shum, E. Y., Song, H.-W.,  
912 Corbett, M. A., Gifford, W. D., Gecz, J., Pfaff, S. L., & Wilkinson, M. F. (2011).  
913 Identification of a MicroRNA that Activates Gene Expression by Repressing  
914 Nonsense-Mediated RNA Decay. *Molecular Cell*, 42(4), 500–510.  
915 <https://doi.org/10.1016/j.molcel.2011.04.018>
- 916 Buchwald, G., Ebert, J., Basquin, C., Sauliere, J., Jayachandran, U., Bono, F., Hir, H. L., &  
917 Conti, E. (2010). Insights into the recruitment of the NMD machinery from the crystal  
918 structure of a core EJC-UPF3b complex. *Proceedings of the National Academy of  
919 Sciences*, 107(22), 10050–10055. <https://doi.org/10.1073/pnas.1000993107>
- 920 Celik, A., Baker, R., He, F., & Jacobson, A. (2017). High-resolution profiling of NMD targets  
921 in yeast reveals translational fidelity as a basis for substrate selection. *RNA*, 23(5),  
922 735–748. <https://doi.org/10.1261/rna.060541.116>
- 923 Chamieh, H., Ballut, L., Bonneau, F., & Le Hir, H. (2008). NMD factors UPF2 and UPF3  
924 bridge UPF1 to the exon junction complex and stimulate its RNA helicase activity.  
925 *Nature Structural & Molecular Biology*, 15(1), 85–93.  
926 <https://doi.org/10.1038/nsmb1330>
- 927 Chan, W.-K., Bhalla, A. D., Le Hir, H., Nguyen, L. S., Huang, L., Gécz, J., & Wilkinson, M. F.  
928 (2009). A UPF3-mediated regulatory switch that maintains RNA surveillance. *Nature  
929 Structural & Molecular Biology*, 16(7), 747–753. <https://doi.org/10.1038/nsmb.1612>
- 930 Chan, W.-K., Huang, L., Gudikote, J. P., Chang, Y.-F., Imam, J. S., MacLean II, J. A., &  
931 Wilkinson, M. F. (2007). An alternative branch of the nonsense-mediated decay  
932 pathway. *The EMBO Journal*, 26(7), 1820–1830.  
933 <https://doi.org/10.1038/sj.emboj.7601628>
- 934 Danecek, P., Bonfield, J. K., Liddle, J., Marshall, J., Ohan, V., Pollard, M. O., Whitwham, A.,  
935 Keane, T., McCarthy, S. A., Davies, R. M., & Li, H. (2021). Twelve years of SAMtools  
936 and BCFtools. *GigaScience*, 10(2). <https://doi.org/10.1093/gigascience/giab008>
- 937 Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P.,  
938 Chaisson, M., & Gingeras, T. R. (2013). STAR: Ultrafast universal RNA-seq aligner.  
939 *Bioinformatics*, 29(1), 15–21. <https://doi.org/10.1093/bioinformatics/bts635>
- 940 Eberle, A. B., Stalder, L., Mathys, H., Orozco, R. Z., & Mühlemann, O. (2008).  
941 Posttranscriptional Gene Regulation by Spatial Rearrangement of the 3' Untranslated  
942 Region. *PLOS Biology*, 6(4), e92. <https://doi.org/10.1371/journal.pbio.0060092>
- 943 Gehring, N. H., Kunz, J. B., Neu-Yilik, G., Breit, S., Viegas, M. H., Hentze, M. W., & Kulozik,  
944 A. E. (2005). Exon-Junction Complex Components Specify Distinct Routes of  
945 Nonsense-Mediated mRNA Decay with Differential Cofactor Requirements.  
946 *Molecular Cell*, 20(1), 65–75. <https://doi.org/10.1016/j.molcel.2005.08.012>
- 947 Gerbracht, J. V., Boehm, V., Britto-Borges, T., Kallabis, S., Wiederstein, J. L., Ciriello, S.,  
948 Aschemeier, D. U., Krüger, M., Frese, C. K., Altmüller, J., Dieterich, C., & Gehring, N.  
949 H. (2020). CASC3 promotes transcriptome-wide activation of nonsense-mediated  
950 decay by the exon junction complex. *Nucleic Acids Research*, 48(15), 8626–8644.  
951 <https://doi.org/10.1093/nar/gkaa564>
- 952 He, F., Brown, A. H., & Jacobson, A. (1997). Upf1p, Nmd2p, and Upf3p are interacting  
953 components of the yeast nonsense-mediated mRNA decay pathway. *Molecular and  
954 Cellular Biology*, 17(3), 1580–1594. <https://doi.org/10.1128/MCB.17.3.1580>
- 955 He, F., & Jacobson, A. (2015). Nonsense-Mediated mRNA Decay: Degradation of Defective  
956 Transcripts Is Only Part of the Story. *Annual Review of Genetics*, 49(1), 339–366.  
957 <https://doi.org/10.1146/annurev-genet-112414-054639>

- 958 Hir, H. L., Saulière, J., & Wang, Z. (2016). The exon junction complex as a node of post-  
959 transcriptional networks. *Nature Reviews Molecular Cell Biology*, 17(1), 41–54.  
960 <https://doi.org/10.1038/nrm.2015.7>
- 961 Hogg, J. R., & Goff, S. P. (2010). Upf1 Senses 3'UTR Length to Potentiate mRNA Decay.  
962 *Cell*, 143(3), 379–389. <https://doi.org/10.1016/j.cell.2010.10.005>
- 963 Huang, L., Lou, C.-H., Chan, W., Shum, E. Y., Shao, A., Stone, E., Karam, R., Song, H.-W.,  
964 & Wilkinson, M. F. (2011). RNA Homeostasis Governed by Cell Type-Specific and  
965 Branched Feedback Loops Acting on NMD. *Molecular Cell*, 43(6), 950–961.  
966 <https://doi.org/10.1016/j.molcel.2011.06.031>
- 967 Huang, L., Shum, E. Y., Jones, S. H., Lou, C.-H., Dumdie, J., Kim, H., Roberts, A. J., Jolly,  
968 L. A., Espinoza, J. L., Skarbrevik, D. M., Phan, M. H., Cook-Andersen, H., Swerdlow,  
969 N. R., Gecz, J., & Wilkinson, M. F. (2018). A Upf3b -mutant mouse model with  
970 behavioral and neurogenesis defects. *Molecular Psychiatry*, 23(8), 1773–1786.  
971 <https://doi.org/10.1038/mp.2017.173>
- 972 Ivanov, P. V., Gehring, N. H., Kunz, J. B., Hentze, M. W., & Kulozik, A. E. (2008).  
973 Interactions between UPF1, eRFs, PABP and the exon junction complex suggest an  
974 integrated model for mammalian NMD pathways. *The EMBO Journal*, 27(5), 736–  
975 747. <https://doi.org/10.1038/emboj.2008.17>
- 976 Kadlec, J., Izaurralde, E., & Cusack, S. (2004). The structural basis for the interaction  
977 between nonsense-mediated mRNA decay factors UPF2 and UPF3. *Nature*  
978 *Structural & Molecular Biology*, 11(4), 330–337. <https://doi.org/10.1038/nsmb741>
- 979 Karousis, E. D., Gurzeler, L.-A., Annibaldis, G., Dreos, R., & Mühlemann, O. (2020). Human  
980 NMD ensues independently of stable ribosome stalling. *Nature Communications*,  
981 11(1), 4134. <https://doi.org/10.1038/s41467-020-17974-z>
- 982 Karousis, E. D., & Mühlemann, O. (2019). Nonsense-Mediated mRNA Decay Begins Where  
983 Translation Ends. *Cold Spring Harbor Perspectives in Biology*, 11(2), a032862.  
984 <https://doi.org/10.1101/cshperspect.a032862>
- 985 Kashima, I., Yamashita, A., Izumi, N., Kataoka, N., Morishita, R., Hoshino, S., Ohno, M.,  
986 Dreyfuss, G., & Ohno, S. (2006). Binding of a novel SMG-1–Upf1–eRF1–eRF3  
987 complex (SURF) to the exon junction complex triggers Upf1 phosphorylation and  
988 nonsense-mediated mRNA decay. *Genes & Development*, 20(3), 355–367.  
989 <https://doi.org/10.1101/gad.1389006>
- 990 Kishor, A., Fritz, S. E., & Hogg, J. R. (2019). Nonsense-mediated mRNA decay: The  
991 challenge of telling right from wrong in a complex transcriptome. *WIREs RNA*, 10(6),  
992 e1548. <https://doi.org/10.1002/wrna.1548>
- 993 Kunz, J. B., Neu-Yilik, G., Hentze, M. W., Kulozik, A. E., & Gehring, N. H. (2006). Functions  
994 of hUpf3a and hUpf3b in nonsense-mediated mRNA decay and translation. *RNA*,  
995 12(6), 1015–1022. <https://doi.org/10.1261/rna.12506>
- 996 Kurosaki, T., Popp, M. W., & Maquat, L. E. (2019). Quality and quantity control of gene  
997 expression by nonsense-mediated mRNA decay. *Nature Reviews Molecular Cell*  
998 *Biology*, 20(7), 406–420. <https://doi.org/10.1038/s41580-019-0126-2>
- 999 Laumonier, F., Shoubridge, C., Antar, C., Nguyen, L. S., Van Esch, H., Kleefstra, T.,  
1000 Briault, S., Fryns, J. P., Hamel, B., Chelly, J., Ropers, H. H., Ronce, N., Blesson, S.,  
1001 Moraine, C., Gécz, J., & Raynaud, M. (2010). Mutations of the UPF3B gene, which  
1002 encodes a protein widely expressed in neurons, are associated with nonspecific  
1003 mental retardation with or without autism. *Molecular Psychiatry*, 15(7), 767–776.  
1004 <https://doi.org/10.1038/mp.2009.14>
- 1005 López-Perrote, A., Castaño, R., Melero, R., Zamarro, T., Kurosawa, H., Ohnishi, T.,  
1006 Uchiyama, A., Aoyagi, K., Buchwald, G., Kataoka, N., Yamashita, A., & Llorca, O.  
1007 (2016). Human nonsense-mediated mRNA decay factor UPF2 interacts directly with  
1008 eRF3 and the SURF complex. *Nucleic Acids Research*, 44(4), 1909–1923.  
1009 <https://doi.org/10.1093/nar/gkv1527>
- 1010 Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of fold change and  
1011 dispersion for RNA-seq data with DESeq2. *Genome Biology*, 15(12), 550.  
1012 <https://doi.org/10.1186/s13059-014-0550-8>

- 1013 Lykke-Andersen, J., Shu, M.-D., & Steitz, J. A. (2000). Human Upf Proteins Target an mRNA  
1014 for Nonsense-Mediated Decay When Bound Downstream of a Termination Codon.  
1015 *Cell*, 103(7), 1121–1131. [https://doi.org/10.1016/S0092-8674\(00\)00214-2](https://doi.org/10.1016/S0092-8674(00)00214-2)
- 1016 Lynch, S. A., Nguyen, L. S., Ng, L. Y., Waldron, M., McDonald, D., & Gecz, J. (2012).  
1017 Broadening the phenotype associated with mutations in UPF3B: Two further cases  
1018 with renal dysplasia and variable developmental delay. *European Journal of Medical*  
1019 *Genetics*, 55(8), 476–479. <https://doi.org/10.1016/j.ejmg.2012.03.010>
- 1020 Ma, Z., Zhu, P., Shi, H., Guo, L., Zhang, Q., Chen, Y., Chen, S., Zhang, Z., Peng, J., &  
1021 Chen, J. (2019). PTC-bearing mRNA elicits a genetic compensation response via  
1022 Upf3a and COMPASS components. *Nature*, 568(7751), 259–263.  
1023 <https://doi.org/10.1038/s41586-019-1057-y>
- 1024 Mabin, J. W., Woodward, L. A., Patton, R. D., Yi, Z., Jia, M., Wysocki, V. H., Bundschuh, R.,  
1025 & Singh, G. (2018). The Exon Junction Complex Undergoes a Compositional Switch  
1026 that Alters mRNP Structure and Nonsense-Mediated mRNA Decay Activity. *Cell*  
1027 *Reports*, 25(9), 2431–2446.e7. <https://doi.org/10.1016/j.celrep.2018.11.046>
- 1028 Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing  
1029 reads. *EMBnet Journal*, 17(1), 10–12. <https://doi.org/10.14806/ej.17.1.200>
- 1030 Medghalchi, S. M., Frischmeyer, P. A., Mendell, J. T., Kelly, A. G., Lawler, A. M., & Dietz, H.  
1031 C. (2001). Rent1, a trans-effector of nonsense-mediated mRNA decay, is essential  
1032 for mammalian embryonic viability. *Human Molecular Genetics*, 10(2), 99–105.  
1033 <https://doi.org/10.1093/hmg/10.2.99>
- 1034 Melero, R., Buchwald, G., Castaño, R., Raabe, M., Gil, D., Lázaro, M., Urlaub, H., Conti, E.,  
1035 & Llorca, O. (2012). The cryo-EM structure of the UPF–EJC complex shows UPF1  
1036 poised toward the RNA 3' end. *Nature Structural & Molecular Biology*, 19(5), 498–  
1037 505. <https://doi.org/10.1038/nsmb.2287>
- 1038 Mendell, J. T., Sharifi, N. A., Meyers, J. L., Martinez-Murillo, F., & Dietz, H. C. (2004).  
1039 Nonsense surveillance regulates expression of diverse classes of mammalian  
1040 transcripts and mutes genomic noise. *Nature Genetics*, 36(10), 1073–1078.  
1041 <https://doi.org/10.1038/ng1429>
- 1042 Natsume, T., Kiyomitsu, T., Saga, Y., & Kanemaki, M. T. (2016). Rapid Protein Depletion in  
1043 Human Cells by Auxin-Inducible Degron Tagging with Short Homology Donors. *Cell*  
1044 *Reports*, 15(1), 210–218. <https://doi.org/10.1016/j.celrep.2016.03.001>
- 1045 Neu-Yilik, G., Raimondeau, E., Eliseev, B., Yeramala, L., Amthor, B., Deniaud, A., Huard, K.,  
1046 Kerschgens, K., Hentze, M. W., Schaffitzel, C., & Kulozik, A. E. (2017). Dual function  
1047 of UPF3B in early and late translation termination. *The EMBO Journal*, 36(20), 2968–  
1048 2986. <https://doi.org/10.15252/embj.201797079>
- 1049 Nguyen, L. S., Jolly, L., Shoubridge, C., Chan, W. K., Huang, L., Laumonier, F., Raynaud,  
1050 M., Hackett, A., Field, M., Rodriguez, J., Srivastava, A. K., Lee, Y., Long, R.,  
1051 Addington, A. M., Rapoport, J. L., Suren, S., Hahn, C. N., Gamble, J., Wilkinson, M.  
1052 F., ... Gecz, J. (2012). Transcriptome profiling of UPF3B/NMD-deficient  
1053 lymphoblastoid cells from patients with various forms of intellectual disability.  
1054 *Molecular Psychiatry*, 17(11), 1103–1115. <https://doi.org/10.1038/mp.2011.163>
- 1055 Patton, R. D., Sanjeev, M., Woodward, L. A., Mabin, J. W., Bundschuh, R., & Singh, G.  
1056 (2020). Chemical crosslinking enhances RNA immunoprecipitation for efficient  
1057 identification of binding sites of proteins that photo-crosslink poorly with RNA. *RNA*,  
1058 rna.074856.120. <https://doi.org/10.1261/rna.074856.120>
- 1059 Peixeiro, I., Inácio, Â., Barbosa, C., Silva, A. L., Liebhaber, S. A., & Romão, L. (2012).  
1060 Interaction of PABPC1 with the translation initiation complex is critical to the NMD  
1061 resistance of AUG-proximal nonsense mutations. *Nucleic Acids Research*, 40(3),  
1062 1160–1173. <https://doi.org/10.1093/nar/gkr820>
- 1063 Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013). Genome  
1064 engineering using the CRISPR-Cas9 system. *Nature Protocols*, 8(11), 2281–2308.  
1065 <https://doi.org/10.1038/nprot.2013.143>

- 1066 Risso, D., Ngai, J., Speed, T. P., & Dudoit, S. (2014). Normalization of RNA-seq data using  
1067 factor analysis of control genes or samples. *Nature Biotechnology*, 32(9), 896–902.  
1068 <https://doi.org/10.1038/nbt.2931>
- 1069 Shum, E. Y., Jones, S. H., Shao, A., Dumdie, J., Krause, M. D., Chan, W.-K., Lou, C.-H.,  
1070 Espinoza, J. L., Song, H.-W., Phan, M. H., Ramaiah, M., Huang, L., McCarrey, J. R.,  
1071 Peterson, K. J., De Rooij, D. G., Cook-Andersen, H., & Wilkinson, M. F. (2016). The  
1072 Antagonistic Gene Paralogs Upf3a and Upf3b Govern Nonsense-Mediated RNA  
1073 Decay. *Cell*, 165(2), 382–395. <https://doi.org/10.1016/j.cell.2016.02.046>
- 1074 Singh, G., Jakob, S., Kleedehn, M. G., & Lykke-Andersen, J. (2007). Communication with  
1075 the Exon-Junction Complex and Activation of Nonsense-Mediated Decay by Human  
1076 Upf Proteins Occur in the Cytoplasm. *Molecular Cell*, 27(5), 780–792.  
1077 <https://doi.org/10.1016/j.molcel.2007.06.030>
- 1078 Singh, G., Kucukural, A., Cenik, C., Leszyk, J. D., Shaffer, S. A., Weng, Z., & Moore, M. J.  
1079 (2012). The Cellular EJC Interactome Reveals Higher-Order mRNP Structure and an  
1080 EJC-SR Protein Nexus. *Cell*, 151(4), 750–764.  
1081 <https://doi.org/10.1016/j.cell.2012.10.007>
- 1082 Singh, G., Rebbapragada, I., & Lykke-Andersen, J. (2008). A Competition between  
1083 Stimulators and Antagonists of Upf Complex Recruitment Governs Human  
1084 Nonsense-Mediated mRNA Decay. *PLOS Biology*, 6(4), e111.  
1085 <https://doi.org/10.1371/journal.pbio.0060111>
- 1086 Smith, T., Heger, A., & Sudbery, I. (2017). UMI-tools: Modeling sequencing errors in Unique  
1087 Molecular Identifiers to improve quantification accuracy. *Genome Research*, 27(3),  
1088 491–499. <https://doi.org/10.1101/gr.209601.116>
- 1089 Sonesson, C., Love, M. I., & Robinson, M. D. (2015). Differential analyses for RNA-seq:  
1090 Transcript-level estimates improve gene-level inferences. *F1000Research*, 4, 1521.  
1091 <https://doi.org/10.12688/f1000research.7563.1>
- 1092 Tani, H., Imamachi, N., Salam, K. A., Mizutani, R., Ijiri, K., Irie, T., Yada, T., Suzuki, Y., &  
1093 Akimitsu, N. (2012). Identification of hundreds of novel UPF1 target transcripts by  
1094 direct determination of whole transcriptome stability. *RNA Biology*, 9(11), 1370–1379.  
1095 <https://doi.org/10.4161/rna.22360>
- 1096 Tarpey, P. S., Lucy Raymond, F., Nguyen, L. S., Rodriguez, J., Hackett, A., Vandeleur, L.,  
1097 Smith, R., Shoubridge, C., Edkins, S., Stevens, C., O'Meara, S., Tofts, C., Barthorpe,  
1098 S., Buck, G., Cole, J., Halliday, K., Hills, K., Jones, D., Mironenko, T., ... Géczy, J.  
1099 (2007). Mutations in UPF3B, a member of the nonsense-mediated mRNA decay  
1100 complex, cause syndromic and nonsyndromic mental retardation. *Nature Genetics*,  
1101 39(9), 1127–1133. <https://doi.org/10.1038/ng2100>
- 1102 Turner, J. M. A. (2007). Meiotic sex chromosome inactivation. *Development*, 134(10), 1823–  
1103 1831. <https://doi.org/10.1242/dev.000018>
- 1104 Wallmeroth, D., Boehm, V., Lackmann, J.-W., Altmueller, J., Dieterich, C., & Gehring, N. H.  
1105 (2021). UPF3A and UPF3B are redundant and modular activators of nonsense-  
1106 mediated mRNA decay in human cells. *BioRxiv*, 2021.07.07.451444.  
1107 <https://doi.org/10.1101/2021.07.07.451444>
- 1108 Wang, W., Czaplinski, K., Rao, Y., & Peltz, S. W. (2001). The role of Upf proteins in  
1109 modulating the translation read-through of nonsense-containing transcripts. *The*  
1110 *EMBO Journal*, 20(4), 880–890. <https://doi.org/10.1093/emboj/20.4.880>
- 1111 Weischenfeldt, J., Damgaard, I., Bryder, D., Theilgaard-Mönch, K., Thoren, L. A., Nielsen, F.  
1112 C., Jacobsen, S. E. W., Nerlov, C., & Porse, B. T. (2008). NMD is essential for  
1113 hematopoietic stem and progenitor cells and for eliminating by-products of  
1114 programmed DNA rearrangements. *Genes & Development*, 22(10), 1381–1396.  
1115 <https://doi.org/10.1101/gad.468808>
- 1116 Wittmann, J., Hol, E. M., & Jäck, H.-M. (2006). HUPF2 Silencing Identifies Physiologic  
1117 Substrates of Mammalian Nonsense-Mediated mRNA Decay. *Molecular and Cellular*  
1118 *Biology*, 26(4), 1272–1287. <https://doi.org/10.1128/MCB.26.4.1272-1287.2006>

- 1119 Woodward, L. A., Mabin, J. W., Gangras, P., & Singh, G. (2017). The exon junction complex:  
1120 A lifelong guardian of mRNA fate. *WIREs RNA*, 8(3), e1411.  
1121 <https://doi.org/10.1002/wrna.1411>
- 1122 Xu, X., Zhang, L., Tong, P., Xun, G., Su, W., Xiong, Z., Zhu, T., Zheng, Y., Luo, S., Pan, Y.,  
1123 Xia, K., & Hu, Z. (2013). Exome sequencing identifies UPF3B as the causative gene  
1124 for a Chinese non-syndrome mental retardation pedigree. *Clinical Genetics*, 83(6),  
1125 560–564. <https://doi.org/10.1111/cge.12014>
- 1126 Yi, Z., Sanjeev, M., & Singh, G. (2021). The Branched Nature of the Nonsense-Mediated  
1127 mRNA Decay Pathway. *Trends in Genetics*, 37(2), 143–159.  
1128 <https://doi.org/10.1016/j.tig.2020.08.010>
- 1129 Yi, Z., & Singh, G. (2021). Chapter Seventeen - RIPiT-Seq: A tandem immunoprecipitation  
1130 approach to reveal global binding landscape of multisubunit ribonucleoproteins. In B.  
1131 Tian (Ed.), *Methods in Enzymology* (Vol. 655, pp. 401–425). Academic Press.  
1132 <https://doi.org/10.1016/bs.mie.2021.03.019>
- 1133 Yusa, K., Zhou, L., Li, M. A., Bradley, A., & Craig, N. L. (2011). A hyperactive piggyBac  
1134 transposase for mammalian applications. *Proceedings of the National Academy of  
1135 Sciences*, 108(4), 1531–1536. <https://doi.org/10.1073/pnas.1008322108>  
1136



1137 **FIGURE LEGENDS**

1138

1139 **Figure 1. Loss of *UPF3B* in human cells affects EJC-mediated NMD.**

1140 A. Schematic of *UPF3B* knockout (UPF3B-KO) strategies using CRISPR-Cas9. *UPF3B*  
1141 locus is in black where rectangles represent exons and horizontal line denotes introns;  
1142 coding region is shown as wider rectangles. Red arrowheads represent guide RNA targeting  
1143 sites. In 3B<sup>KO#1</sup> (top), two guide RNAs delete the UPF2 binding domain (UPF2-BD) of  
1144 *UPF3B* protein coding region as shown. In 3B<sup>KO#2</sup> (bottom), a donor template is used to  
1145 insert puromycin resistant gene (PuroR) and bovine growth hormone (BGH) polyadenylation  
1146 signal at the cut site.

1147 B. Immunoblot of wild-type (WT) and UPF3B-KO cell lines showing levels of proteins on the  
1148 right. In 3B<sup>KO#1</sup>, a smaller UPF3B protein with deletion of amino acids 20-155 (UPF3B $\Delta$ 20-  
1149 155) is expressed. Relative Expression (Rel Exp) of this deletion protein as compared to the  
1150 full-length WT protein along with standard error of mean (SEM) are indicated below lane 2.  
1151 UPF3B antibody recognizes antigen outside the deleted region in 3B<sup>KO#1</sup>. HNRNPA1 is used  
1152 as a loading control.

1153 C-D. Cumulative Distribution Function (CDF) plots of PTC+ isoforms and PTC- isoforms  
1154 from same set of genes. X-axis represents fold change in, (C) 3B<sup>KO#1</sup> versus WT cells each  
1155 with control knockdown (siNC), (D) UPF1 knockdown (siUPF1) versus negative control  
1156 knockdown (siNC) in WT cells. Number of transcripts in each set (n) and p-value from  
1157 Kolmogorov-Smirnov (KS) test comparing the two distributions are shown.

1158 E. Bar plots from isoform specific RT-qPCR analysis showing average fold change (y-axis)  
1159 of PTC+ and PTC- isoforms from genes indicated on the bottom in WT and the two 3B<sup>KO</sup>  
1160 cells identified in the legend on the top right. For each isoform, levels in knockout cells are  
1161 compared to the levels in WT cells (set to 1). Relative levels from each replicate are shown  
1162 by white circles. Error bars indicate standard error of means. The asterisk (\*) represents  
1163 p<0.05 in t-test with null hypothesis of true mean being 1 (n=3).

1164 F. Cumulative Distribution Function (CDF) plots of PTC+ isoforms and PTC- isoforms from  
1165 same set of genes. X-axis represents fold change in UPF1 knockdown (siUPF1) versus  
1166 control knockdown (siNC) in 3B<sup>KO#1</sup> cells. Number of transcripts in each set (n) and p-value  
1167 from Kolmogorov-Smirnov (KS) test comparing the two distributions are shown.

1168

1169 **Figure S1. Changes in gene expression and NMD upon *UPF3B* loss in HCT116 cells.**

1170 A. Alteration in expression levels of known NMD genes in the two 3B<sup>KO</sup> cell lines. RT-qPCR-  
1171 based quantification of expression levels of previously characterized NMD-sensitive genes  
1172 (x-axis) in the two 3B<sup>KO</sup> HCT116 cell lines as compared to their levels in WT cells (set to 1).  
1173 Relative levels from each replicate are shown by white circles. Error bars indicate standard  
1174 error of means. The asterisk (\*) represents p<0.05 in t-test with null hypothesis of true mean  
1175 being 1 (n=3).

1176 B. Immunoblot showing levels of UPF1 and UPF3B proteins in WT and 3B<sup>KO#1</sup> cells  
1177 (indicated on top) that were transfected with negative control (siNC) or UPF1-targeting  
1178 (siUPF1) siRNAs. HNRNPA1 is a loading control.

1179 C-E. MA plots showing differential transcript expression in RNA-Seq samples from (C)  
1180 3B<sup>KO#1</sup> (siNC) versus WT (siNC), (D) UPF1-KD (siUPF1) versus control knockdown (siNC) in  
1181 3B<sup>KO#1</sup>, and (E) UPF1-KD (siUPF1) versus control knockdown (siNC) in WT cells. Each dot  
1182 represents one transcript isoform with average read counts on the x axis and log<sub>2</sub> fold  
1183 change on the y axis. Transcripts that are significantly (adjusted p-value < 0.05) up (red)- or  
1184 down (blue)- regulated >1.5-fold and their counts are indicated.

1185 F. Isoform specific RT-qPCR measuring changes in levels of PTC+ and PTC- isoforms  
1186 expressed from the indicated genes in WT and 3B<sup>KO</sup> cells. Fold changes are with respect to  
1187 the levels of PTC- isoforms in WT cells. Relative levels from each replicate are shown by

1188 white circles. Error bars indicate standard error of means. The asterisk (\*) represents  $p < 0.05$   
1189 in t-test with null hypothesis of true mean being 1 ( $n=3$ ).

1190 G, H. CDF plots showing fold change in levels of transcripts with long, medium and short 3'  
1191 UTRs in (F) UPF1 (siUPF1) versus control (siNC) knockdown in WT cells, and (G)  $3B^{KO\#1}$   
1192 versus WT cells each transfected with control siRNA (siNC). p-values shown are from KS  
1193 test comparing distribution of  $\log_2$  fold changes in medium and long 3'UTR transcript groups  
1194 as compared to the short 3'UTR transcript group. Number of transcripts in each group are  
1195 also shown.

1196

## 1197 **Figure 2. UPF3A activates NMD in the absence of UPF3B.**

1198 A. Immunoblots showing levels of proteins on the right in input or FLAG immunoprecipitates  
1199 (FLAG-IP) from WT and UPF3B-KO cells expressing endogenously FLAG-tagged UPF1  
1200 protein as indicated above each lane. The presence of RNase A during FLAG-IP is indicated  
1201 above each lane.

1202 B. Immunoblots showing levels of proteins on the right in cells indicated above each lane. At  
1203 the bottom are relative UPF3A levels after normalization to HNRNPA1 levels ( $n=4$ ).

1204 C. Immunoblots showing levels of proteins (right) in input and immunoprecipitates from IP  
1205 with normal rabbit IgG (IgG-IP) or antibody targeting EIF4A3 (EIF4A3-IP) from WT and  
1206 UPF3B-KO cells.

1207 D, E. CDF plots of PTC+ isoforms and PTC- isoforms from same set of genes. X-axis  
1208 represents fold change upon UPF3A knockdown (siUPF3A) versus negative control  
1209 knockdown (siNC) in, (D) WT cells, and (E)  $3B^{KO\#1}$  cells. Number of transcripts in each set  
1210 ( $n$ ) and p-value from KS test comparing the two distributions are shown on each plot.

1211 F, G. CDF plots of UPF3B-dependent (F) and -independent (G) PTC+ isoforms and PTC-  
1212 isoforms from same set of genes. X-axis represents fold change upon UPF3A knockdown  
1213 (siUPF3A) versus negative control knockdown (siNC) in  $3B^{KO\#1}$  cells. Number of transcripts  
1214 in each set ( $n$ ) and p-value from KS test comparing the two distributions are shown on each  
1215 plot.

1216 H. Bar plot showing average fold change as measured by isoform specific RT-qPCR of  
1217 PTC+ and PTC- isoform from genes indicated on the bottom in WT and two independent  
1218 clones of  $3A^{KO}$ ,  $3B^{KO}$ , and  $3D^{KO}$  cells. Relative levels from each replicate are shown by white  
1219 circles. Error bars indicate standard error of means. The asterisk (\*) represents  $p < 0.05$  in t-  
1220 test with null hypothesis of true mean being 1 ( $n=3$ ).

1221

## 1222 **Figure S2. UPF3A activates NMD in the absence of UPF3B.**

1223 A. Western blots showing levels of EJC/UPF proteins or HNRNPA1 in input, normal rabbit  
1224 IgG-IP or CASC3-IP fractions from WT and  $3B^{KO\#1}$  cells.

1225 B. Western blots showing levels of EJC/UPF proteins or HNRNPA1 in input or FLAG-  
1226 MAGOH followed by MYC-UPF2 tandem-IP fractions from WT,  $3A^{KO\#2}$ , and  $3B^{KO\#2}$  cells.  
1227 Samples were RNase A treated during the FLAG IP. The asterisk (\*) represents the mouse  
1228 heavy chain of the MYC-tag antibody.

1229 C. Immunoblot showing levels of UPF3A and UPF3B proteins in WT and  $3B^{KO\#1}$  cells  
1230 (indicated on top) that were transfected with negative control (siNC) or UPF3A-targeting  
1231 (siUPF3A) siRNAs. HNRNPA1 is a loading control.

1232 D. MA plots showing differential transcript expression in RNA-Seq samples from UPF3A-KD  
1233 (siUPF3A) versus control knockdown (siNC) in WT HCT116 cells. Each dot represents one  
1234 transcript isoform with average read counts on the x-axis and  $\log_2$  fold change on the y-axis.  
1235 Red and blue dots represent  $>1.5$ -fold up- or down- regulated transcripts, respectively, that  
1236 are significantly changed (adjusted p-value  $< 0.05$ ).

1237 E. Schematic of UPF3A knockout (UPF3B-KO) strategies using CRISPR-Cas9. UPF3A  
1238 locus is in black where rectangles represent exons and horizontal line denotes introns;

1239 coding region is shown as wider rectangles. Red arrowheads represent guide RNA targeting  
1240 sites. In 3A<sup>KO#1</sup> (top), two guide RNAs delete first and the second exons of UPF3A protein  
1241 coding region. In 3A<sup>KO#2</sup> (bottom), a donor template is used to insert blasticidin resistant  
1242 gene (BlasticidinR) and Simian Virus 40 (SV40) polyadenylation signal at the cut site.  
1243 F. Immunoblot of UPF3A and UPF3B proteins in WT, 3A<sup>KO</sup>, 3B<sup>KO</sup>, and 3<sup>DKO</sup> cells. EIF4A3 is  
1244 used as a loading control.  
1245 G. Isoform specific RT-qPCR of PTC+ and PTC- isoforms from the indicated genes in WT,  
1246 3A<sup>KO</sup>, 3B<sup>KO</sup>, and 3<sup>DKO</sup> cells. Relative levels from each replicate are shown by white circles  
1247 Error bars indicate standard error of means. The asterisk (\*) represents p<0.05 in t-test with  
1248 null hypothesis of true mean being 1 (n=3).  
1249 H, I. CDF plots showing fold change in levels of transcripts with short, medium and long  
1250 3'UTRs in UPF3A (siUPF3A) versus control (siNC) knockdown in (F) WT cells, and (G)  
1251 3B<sup>KO#1</sup> cells.

1252

### 1253 **Figure 3. CASC3 contributes to UPF3-dependent NMD.**

1254 A, B. Western blots showing levels of EJC proteins or HNRNPA1 (control) in input, IgG IP or  
1255 EIF4A3 IP following overexpression (OE) of CASC3 wild-type (WT) and EJC binding  
1256 deficient (HDAA) mutant proteins in (A) HeLa Tet-off cells, and (B) 3B<sup>KO</sup> HeLa Tet-off cells.  
1257 Ramps above lanes indicate expression levels of the CASC3 proteins.  
1258 C. Western blots showing levels of EJC/UPF proteins and HNRNPA1 in input and FLAG  
1259 followed by EIF4A3 tandem IP from HCT116 cells expressing the FLAG-tagged protein  
1260 indicated above each lane. Quantifications of UPF3B and CASC3 protein enrichment from  
1261 two replicates are shown at the bottom.  
1262 D. Meta-exon plot showing read distributions within the 100 nucleotide (nt) window from the  
1263 exon 3' end in RIPiT-Seq replicates of MAGOH:EIF4A3, UPF3B:EIF4A3, and  
1264 CASC3:EIF4A3. The black vertical line indicates the -24 nt position.  
1265 E. Venn diagram showing the degree of overlap between genes significantly enriched in  
1266 CASC3:EIF4A3 EJC and UPF3B:EIF4A3 EJC occupancy as compared to MAGOH:EIF4A3  
1267 EJC occupancy.  
1268 F. Scatter plot comparing log<sub>2</sub>-transformed fold change in occupancy of CASC3:EIF4A3  
1269 EJC as compared to MAGOH:EIF4A3 EJC (x-axis) and UPF3B:EIF4A3 EJC compared to  
1270 MAGOH:EIF4A3 EJC. Each dot represents a gene where gene-level occupancy of each  
1271 EJC composition was quantified at the canonical position for EJC footprints. Pearson  
1272 correlation coefficient is shown on the top left.  
1273 G. Scatter plot showing a comparison between relative UPF3B occupancy on gene  
1274 (UPF3B:EIF4A3 RIPiT-Seq normalized to MAGOH:EIF4A3 RIPiT-Seq) on x-axis and NMD  
1275 efficiency of each gene on the y-axis. For each gene in this analysis, NMD efficiency is the  
1276 highest fold change (in 3B<sup>KO#1</sup> siUPF3A to WT siNC) observed for its PTC+ isoform. R<sup>2</sup> from  
1277 the linear regression fit is shown on the top left.  
1278 H. Bar plots showing fold changes measured by isoform specific RT-qPCR of PTC+ and  
1279 PTC- isoform from genes indicated on the bottom in WT and CASC3-KO HCT116 cells.  
1280 Relative levels from each replicate are shown by white circles. Error bars indicate standard  
1281 error of means. The asterisk (\*) represents p<0.05 in t-test with null hypothesis of true mean  
1282 being 1 (n=3).

1283

### 1284 **Figure S3. CASC3 regulates UPF3-dependent NMD.**

1285 A. Schematic of *UPF3B* knockout in HeLa Tet-off cells using CRISPR-Cas9. Red arrows  
1286 represent two guide RNA targeting sites which will lead to the deletion of the first exon.  
1287 B. Protein immunoblot of UPF3B protein in WT and 3B<sup>KO</sup> HeLa cells. HNRNPA1 is a loading  
1288 control.

1289 C. Western blots showing proteins on the right in input and EIF4A3-IP from WT and 3B<sup>KO</sup>  
1290 HeLa cells. Normal rabbit IgG is used for control IP.  
1291 D. Western blots as in C from HeLa WT and 3B<sup>KO</sup> cells transfected with either siNC or  
1292 siCASC3.  
1293 E. Meta-exon plot of MAGOH:EIF4A3, UPF3B:EIF4A3, and CASC3:EIF4A3 RIPiT-Seq read-  
1294 distribution in the 100 nt region from the exon 5' end.  
1295 F, G. Venn diagram of significantly enriched/depleted genes in CASC3:EIF4A3 or  
1296 UPF3B:EIF4A3 RIPiT-Seq samples as compared to MAGOH:EIF4A3 RIPiT-Seq.  
1297 H, I. Scatter plots showing a comparison between gene-level EJC occupancy and NMD  
1298 efficiency. UPF3B:EIF3A3 (H), or MAGOH:EIF4A3 (I) RIPiT-Seq signal normalized to  
1299 expression level of individual genes is on the x-axis and NMD efficiency of each gene on the  
1300 y-axis. For each gene in this analysis, NMD efficiency is the highest fold change (in 3B<sup>KO#1</sup>  
1301 siUPF3A to WT siNC) observed for its PTC+ isoform. R<sup>2</sup> from the linear regression fit is  
1302 shown on the top left.  
1303 J. Protein immunoblot of CASC3 protein in WT and CASC-KO HeLa cells. HNRNPA1 is a  
1304 loading control.

1305

1306 **Figure 4. NMD activity in human cells in the absence of both UPF3 paralogs.**

1307 A, B. CDF plots of PTC+ and PTC- isoforms from same set of genes. X-axis represents log<sub>2</sub>  
1308 fold change upon UPF2 knockdown as compared to control knockdown in, (A) WT cells, and  
1309 (B) 3<sup>DKO#2</sup> cells.

1310 C, D. CDF plots of PTC+ and PTC- isoforms from same set of genes. X-axis represents fold  
1311 change upon UPF1 knockdown as compared to control knockdown in, (A) WT cells, and (B)  
1312 3<sup>DKO#2</sup> cells. (Figure 4A is the same as Figure 1D.)

1313 E, F. CDF plots of UPF3B-independent (E) and -dependent (F) PTC+ and PTC- isoforms  
1314 from same set of genes. X-axis represents fold change upon UPF1 knockdown (siUPF1)  
1315 versus negative control knockdown (siNC) in 3<sup>DKO#2</sup> cells. Number of transcripts in each set  
1316 (n) and p-value from KS test comparing the two distributions are shown on each plot.

1317

1318 **Figure S4. NMD in the absence of both UPF3 paralogs.**

1319 A. Immunoblots showing levels of UPF1 and UPF2 proteins in 3<sup>DKO#2</sup> cells that were  
1320 transfected with negative control (siNC), UPF1-targeting (siUPF1), or UPF2-targeting  
1321 (siUPF2) siRNAs. HNRNPA1 is a loading control.

1322 B, C. MA plots showing transcript-level changes upon UPF2 (siUPF2) knockdown as  
1323 compared to control knockdown (siNC) in, (B) WT cells, and (C) 3<sup>DKO#2</sup> cells. Each dot  
1324 represents one transcript with average read counts on the x-axis and log<sub>2</sub> fold change on the  
1325 y-axis. Red and blue dots represent transcripts up- or down- regulated more than 1.5-fold  
1326 with an adjusted p-value < 0.05; these counts are shown on each plot.

1327

1328 **Figure 5. Human UPF3 paralogs differ in NMD activity.**

1329 A, B. Northern blots showing levels of β-globin reporter mRNAs in, (A) wild-type HeLa Tet-off  
1330 cells, and (B) UPF3B knockout HeLa Tet-off cells. β39 is a tetracycline (Tet)-inducible  
1331 reporter with a PTC at codon 39 whose levels are shown at different timepoints after  
1332 transcriptional shut-off (chase) as indicated above each lane. β-GAP is a stable,  
1333 constitutively-expressed, longer β-globin mRNA used as transfection control. Proteins  
1334 overexpressed (OE) in each condition are indicated on top and reporter mRNA half-lives  
1335 (t<sub>1/2</sub>) along with standard error of means are on the bottom.

1336 C. Schematic of human UPF3A, UPF3B and the UPF3A chimeric proteins where UPF3A  
1337 domains are replaced by the corresponding domains from UPF3B (see material and  
1338 methods for detailed domain definition). Previously characterized UPF2 binding domain  
1339 (UPF2-BD) and EJC-binding motif (EBM) are shown.

1340 D. Northern blot showing steady-state levels of  $\beta$ 39 NMD reporter and  $\beta$ -GAP control in  
1341 HeLa Tet-off UPF3B knockout cells upon overexpression of wild-type UPF3 proteins or  
1342 different UPF3A chimeric proteins indicated above each lane. Below each lane, relative fold-  
1343 change (Rel. F.C.) indicates  $\beta$ 39 reporter levels (normalized to  $\beta$ -GAP control) as compared  
1344 to the normalized  $\beta$ 39 reporter levels in UPF3B expressing cells.

1345 E. Immunoblot showing levels of EJC proteins or HNRNPA1 in input or EIF4A3-IP from  
1346  $3^{DKO\#2}$  cells expressing different UPF3 proteins or EGFP as a control as indicated above  
1347 each lane. Relative IP of FLAG-tagged proteins are quantified against EIF4A3.

1348

1349 **Figure S5. UPF3 paralogs differ in NMD activity.**

1350 A, B. Protein immunoblots of FLAG-IP from  $3^{DKO\#2}$  cells expressing different FLAG-tagged  
1351 human UPF3 proteins or their chimeras using Tet-on 3G system. HNRNPA1 is used as  
1352 loading control and RNase A digestion control. FLAG-EGFP is used as an IP control.

1353

1354 **Figure 6. EJC binding is dispensable for NMD activity of UPF3.**

1355 A. Protein sequence alignment of UPF3 C-terminal regions from different mammalian  
1356 species.

1357 B. Immunoblot showing levels of EJC and UPF proteins (on the right) in input or FLAG-IP  
1358 samples from  $3^{DKO\#2}$  cells expressing different FLAG-tagged proteins indicated above each  
1359 lane.

1360 C. Bar plots showing isoform specific RT-qPCR-based measurement of relative levels of  
1361 PTC+ and PTC- isoforms of genes indicated below from wild-type (WT) or  $3^{DKO\#2}$  cells  
1362 expressing the specified proteins. Relative levels from each replicate are shown by white  
1363 circles. Error bars indicate standard error of means. The asterisk (\*) represents  $p < 0.05$  in t-  
1364 test with null hypothesis of true mean being 1 (n=3).

1365

1366 **Figure S6. EJC interaction ability of human and mouse UPF3A proteins.**

1367 Protein immunoblots of input and FLAG-IP from WT and  $3^{DKO\#2}$  cells FLAG-tagged human or  
1368 mouse UPF3A as indicated above the lanes. HNRNPA1 is a loading and RNase A digestion  
1369 control.

1370


1371 **Figure 7. A model for UPF3 function in EJC-enhanced NMD.**

1372 A. Top: In UPF3-dependent NMD, prior to UPF1 activation, CASC3-EJC enhances the  
1373 presence of UPF3B and UPF2 on exon-exon junctions. UPF3A can replace UPF3B when  
1374 UPF3B levels are insufficient. Such enhanced concentration of UPF3 and UPF2 in 3'UTR  
1375 can later facilitate the formation of NMD complex with UPF1 (dashed arrow at the top).  
1376 Bottom: During NMD activation, UPF3-eRF3 association is likely to play an important role in  
1377 sensing aberrant translation termination. While EJC might still play a role during NMD  
1378 activation, its association with UPF3 is dispensable for NMD. Red double-headed arrow  
1379 signifies possible UPF complex-EJC communication independently of UPF3.

1380 B. NMD can occur in UPF3-independent manner. It remains possible that EJC can still  
1381 communicate with premature termination complex in a UPF3-, and UPF2-independent  
1382 manner to elicit mRNA decay (red dashed double-headed arrow).

1383

# Figure 1



**Figure 1. Loss of UPF3B in human cells affects EJC-mediated NMD.**

A. Schematic of UPF3B knockout (UPF3B-KO) strategies using CRISPR-Cas9. UPF3B locus is in black where rectangles represent exons and horizontal line denotes introns; coding region is shown as wider rectangles. Red arrowheads represent guide RNA targeting sites. In 3B<sup>KO#1</sup> (top), two guide RNAs delete the UPF2 binding domain (UPF2-BD) of UPF3B protein coding region as shown. In 3B<sup>KO#2</sup> (bottom), a donor template is used to insert puromycin resistant gene (PuroR) and bovine growth hormone (BGH) polyadenylation signal at the cut site.


B. Immunoblot of wild-type (WT) and 3B<sup>KO</sup> cell lines showing levels of proteins on the right. In 3B<sup>KO#1</sup>, a smaller UPF3B protein with deletion of amino acids 20-155 (UPF3B $\Delta$ 20-155) is expressed. Relative Expression (Rel Exp) of this deletion protein as compared to the full-length WT protein along with standard error of mean (SEM) are indicated below lane 2. UPF3B antibody recognizes antigen outside the deleted region in 3B<sup>KO#1</sup>. HNRNPA1 is used as a loading control.

C-D. Cumulative Distribution Function (CDF) plots of PTC+ isoforms and PTC- isoforms from same set of genes. X-axis represents fold change in, (C) 3B<sup>KO#1</sup> versus WT cells each with control knockdown (siNC), (D) UPF1 knockdown (siUPF1) versus negative control knockdown (siNC) in WT cells. Number of transcripts in each set (n) and p-value from Kolmogorov-Smirnov (KS) test comparing the two distributions are shown.

E. Bar plots from isoform specific RT-qPCR analysis showing average fold change (y-axis) of PTC+ and PTC- isoforms from genes indicated on the bottom in WT and the two 3BKO cells identified in the legend on the top right. For each isoform, levels in knockout cells are compared to the levels in WT cells (set to 1). Relative levels from each replicate are shown by white circles. Error bars indicate standard error of means. The asterisk (\*) represents p < 0.05 in t-test with null hypothesis of true mean being 1 (n=3).

F. Cumulative Distribution Function (CDF) plots of PTC+ isoforms and PTC- isoforms from same set of genes. X-axis represents fold change in UPF1 knockdown (siUPF1) versus control knockdown (siNC) in 3B<sup>KO#1</sup> cells. Number of transcripts in each set (n) and p-value from Kolmogorov-Smirnov (KS) test comparing the two distributions are shown.

# Figure 2



**Figure 2. UPF3A activates NMD in the absence of UPF3B.**

A. Immunoblots showing levels of proteins on the right in input or FLAG immunoprecipitates (FLAG-IP) from WT and 3B<sup>KO</sup> cells expressing endogenously FLAG-tagged UPF1 protein as indicated above each lane. The presence of RNase A during FLAG-IP is indicated above each lane.

B. Immunoblots showing levels of proteins on the right in cells indicated above each lane. At the bottom are relative UPF3A levels after normalization to HNRNPA1 levels (n=4).


C. Immunoblots showing levels of proteins (right) in input and immunoprecipitates from IP with normal rabbit IgG (IgG-IP) or antibody targeting EIF4A3 (EIF4A3-IP) from WT and 3B<sup>KO</sup> cells.

D, E. CDF plots of PTC+ isoforms and PTC- isoforms from same set of genes. X-axis represents fold change upon UPF3A knockdown (siUPF3A) versus negative control knockdown (siNC) in, (D) WT cells, and (E) 3B<sup>KO</sup>#1 cells. Number of transcripts in each set (n) and p-value from KS test comparing the two distributions are shown on each plot.

F, G. CDF plots of UPF3B-dependent (F) and -independent (G) PTC+ isoforms and PTC- isoforms from same set of genes. X-axis represents fold change upon UPF3A knockdown (siUPF3A) versus negative control knockdown (siNC) in 3B<sup>KO</sup>#1 cells. Number of transcripts in each set (n) and p-value from KS test comparing the two distributions are shown on each plot.

H. Bar plot showing average fold change as measured by isoform specific RT-qPCR of PTC+ and PTC- isoform from genes indicated on the bottom in WT and two independent clones of 3A<sup>KO</sup>, 3B<sup>KO</sup>, and 3DKO cells. Relative levels from each replicate are shown by white circles. Error bars indicate standard error of means. The asterisk (\*) represents p<0.05 in t-test with null hypothesis of true mean being 1 (n=3).

# Figure 3



**Figure 3. CASC3 contributes to UPF3-dependent NMD.**

A, B. Western blots showing levels of EJC proteins or HNRNPA1 (control) in input, IgG IP or EIF4A3 IP following overexpression (OE) of CASC3 wild-type (WT) and EJC binding deficient (HDAA) mutant proteins in (A) HeLa Tet-off cells, and (B) 3B<sup>KO</sup> HeLa Tet-off cells. Ramps above lanes indicate expression levels of the CASC3 proteins.

C. Western blots showing levels of EJC/UPF proteins and HNRNPA1 in input and FLAG followed by EIF4A3 tandem IP from HCT116 cells expressing the FLAG-tagged protein indicated above each lane. Quantifications of UPF3B and CASC3 protein enrichment from two replicates are shown at the bottom.

D. Meta-exon plot showing read distributions within the 100 nucleotide (nt) window from the exon 3' end in RIPit-Seq replicates of MAGOH:EIF4A3, UPF3B:EIF4A3, and CASC3:EIF4A3. The black vertical line indicates the -24 nt position.

E. Venn diagram showing the degree of overlap between genes significantly enriched in CASC3:EIF4A3 EJC and UPF3B:EIF4A3 EJC occupancy as compared to MAGOH:EIF4A3 EJC occupancy.


F. Scatter plot comparing log<sub>2</sub>-transformed fold change in occupancy of CASC3:EIF4A3 EJC as compared to MAGOH:EIF4A3 EJC (x-axis) and UPF3B:EIF4A3 EJC compared to MAGOH:EIF4A3 EJC. Each dot represents a gene where gene-level occupancy of each EJC composition was quantified at the canonical position for EJC footprints. Pearson correlation coefficient is shown on the top left.

G. Scatter plot showing a comparison between relative UPF3B occupancy on gene (UPF3B:EIF4A3 RIPit-Seq normalized to MAGOH:EIF4A3 RIPit-Seq) on x-axis and NMD efficiency of each gene on the y-axis. For each gene in this analysis, NMD efficiency is the highest fold change (in 3BKO#1 siUPF3A to WT siNC) observed for its PTC+ isoform. R<sup>2</sup> from the linear regression fit is shown on the top left.

H. Bar plots showing fold changes measured by isoform specific RT-qPCR of PTC+ and PTC- isoform from genes indicated on the bottom in WT and CASC3-KO HCT116 cells. Relative levels from each replicate are shown by white circles. Error bars indicate standard error of means. The asterisk (\*) represents p<0.05 in t-test with null hypothesis of true mean being 1 (n=3).



# Figure 4




**Figure 4. NMD activity in human cells in the absence of both UPF3 paralogs.**

A, B. CDF plots of PTC+ and PTC- isoforms from same set of genes. X-axis represents log2 fold change upon UPF2 knockdown as compared to control knockdown in, (A) WT cells, and (B) 3<sup>DKO#2</sup> cells.

C, D. CDF plots of PTC+ and PTC- isoforms from same set of genes. X-axis represents fold change upon UPF1 knockdown as compared to control knockdown in, (A) WT cells, and (B) 3<sup>DKO#2</sup> cells. (Figure 4A is the same as Figure 1D.)

E, F. CDF plots of UPF3B-independent (E) and -dependent (F) PTC+ and PTC- isoforms from same set of genes. X-axis represents fold change upon UPF1 knockdown (siUPF1) versus negative control knockdown (siNC) in 3<sup>DKO#2</sup> cells. Number of transcripts in each set (n) and p-value from KS test comparing the two distributions are shown on each plot.

# Figure 5



**Figure 5. Human UPF3 paralogs differ in NMD activity.**

A, B. Northern blots showing levels of  $\beta$ -globin reporter mRNAs in, (A) wild-type HeLa Tet-off cells, and (B) UPF3B knockout HeLa Tet-off cells.  $\beta$ 39 is a tetracycline (Tet)-inducible reporter with a PTC at codon 39 whose levels are shown at different timepoints after transcriptional shut-off (chase) as indicated above each lane.  $\beta$ -GAP is a stable, constitutively-expressed, longer  $\beta$ -globin mRNA used as transfection control. Proteins overexpressed (OE) in each condition are indicated on top and reporter mRNA half-lives (t1/2) along with standard error of means are on the bottom.

C. Schematic of human UPF3A, UPF3B and the UPF3A chimeric proteins where UPF3A domains are replaced by the corresponding domains from UPF3B (see material and methods for detailed domain definition). Previously characterized UPF2 binding domain (UPF2-BD) and EJC-binding motif (EBM) are shown.

D. Northern blot showing steady-state levels of  $\beta$ 39 NMD reporter and  $\beta$ -GAP control in HeLa Tet-off UPF3B knockout cells upon overexpression of wild-type UPF3 proteins or different UPF3A chimeric proteins indicated above each lane. Below each lane, relative fold-change (Rel. F.C.) indicates  $\beta$ 39 reporter levels (normalized to  $\beta$ -GAP control) as compared to the normalized  $\beta$ 39 reporter levels in UPF3B expressing cells.

E. Immunoblot showing levels of EJC proteins or HNRNPA1 in input or EIF4A3-IP from 3<sup>DKO#2</sup> cells expressing different UPF3 proteins or EGFP as a control as indicated above each lane. Relative IP of FLAG-tagged proteins are quantified against EIF4A3.

# Figure 6





Figure 6. EJC binding is dispensable for NMD activity of UPF3.

A. Protein sequence alignment of UPF3 C-terminal regions from different mammalian species.

B. Immunoblot showing levels of EJC and UPF proteins (on the right) in input or FLAG-IP samples from 3<sup>DKO#2</sup> cells expressing different FLAG-tagged proteins indicated above each lane.

C. Bar plots showing isoform specific RT-qPCR-based measurement of relative levels of PTC+ and PTC- isoforms of genes indicated below from wild-type (WT) or 3<sup>DKO#2</sup> cells expressing the specified proteins. Relative levels from each replicate are shown by white circles. Error bars indicate standard error of means. The asterisk (\*) represents  $p < 0.05$  in t-test with null hypothesis of true mean being 1 ( $n=3$ ).

# Figure 7



**Figure 7. A model for UPF3 function in EJC-enhanced NMD.**

A. Top: In UPF3-dependent NMD, prior to UPF1 activation, CASC3-EJC enhances the presence of UPF3B and UPF2 on exon-exon junctions. UPF3A can replace UPF3B when UPF3B levels are insufficient. Such enhanced concentration of UPF3 and UPF2 in 3'UTR can later facilitate the formation of NMD complex with UPF1 (dashed arrow at the top). Bottom: During NMD activation, UPF3-eRF3 association is likely to play an important role in sensing aberrant translation termination. While EJC might still play a role during NMD activation, its association with UPF3 is dispensable for NMD. Red double-headed arrow signifies possible UPF complex-EJC communication independently of UPF3.

B. NMD can occur in UPF3-independent manner. It remains possible that EJC can still communicate with premature termination complex in a UPF3-, and UPF2-independent manner to elicit mRNA decay (red dashed double-headed arrow).